1
|
Nakanishi R, Ozawa H, Toyota N, Mise M, Akutsu R, Fujita S. Acute Infectious Purpura Fulminans Complicated by Bacterial Translocation after Rectal Cancer Surgery: A Case Report. Medicina (Kaunas) 2024; 60:644. [PMID: 38674289 DOI: 10.3390/medicina60040644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/19/2024] [Revised: 04/12/2024] [Accepted: 04/14/2024] [Indexed: 04/28/2024]
Abstract
The patient was a man in his 80s who had undergone laparoscopic anterior resection for rectal cancer. Bowel obstruction occurred on the third postoperative day but improved with a decompression tube by the fifth postoperative day. A high fever (in the 38 °C range) was also observed. Blood culture tests detected two sets of the gram-negative bacilli Klebsiella aerogenes within 24 h of collection. On the seventh postoperative day, the patient subsequently went into septic shock with disseminated intravascular coagulation (DIC). On the eighth postoperative day, the fingertips and toes became black, and the palms and dorsal surfaces of both feet were dark purple due to peripheral circulatory failure. This suggested acute infectious purpura associated with sepsis (acute infectious purpura fulminans (AIPF)). Intensive care was provided; however, the necrosis of both middle fingers worsened, both middle fingers were gangrenous, and the patient died on the thirtieth postoperative day. AIPF is rarely reported, especially in early-onset cases after elective surgery. We encountered a rare complication of bacterial translocation from postoperative bowel obstruction, leading to AIPF.
Collapse
Affiliation(s)
- Ryo Nakanishi
- Department of Colorectal Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya 320-0834, Japan
| | - Heita Ozawa
- Department of Colorectal Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya 320-0834, Japan
| | - Naoyuki Toyota
- Department of Colorectal Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya 320-0834, Japan
| | - Minori Mise
- Department of Colorectal Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya 320-0834, Japan
| | - Ritsuto Akutsu
- Department of Colorectal Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya 320-0834, Japan
| | - Shin Fujita
- Department of Colorectal Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya 320-0834, Japan
| |
Collapse
|
2
|
Goto K, Watanabe J, Nagasaki T, Uemura M, Ozawa H, Kurose Y, Akagi T, Ichikawa N, Iijima H, Inomata M, Taketomi A, Naitoh T. Impact of the endoscopic surgical skill qualification system on conversion to laparotomy after low anterior resection for rectal cancer in Japan (a secondary analysis of the EnSSURE study). Surg Endosc 2024:10.1007/s00464-024-10740-y. [PMID: 38459211 DOI: 10.1007/s00464-024-10740-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Accepted: 01/28/2024] [Indexed: 03/10/2024]
Abstract
BACKGROUND AND AIMS Conversion to laparotomy is among the serious intraoperative complications and carries an increased risk of postoperative complications. In this cohort study, we investigated whether or not the Endoscopic Surgical Skill Qualification System (ESSQS) affects the conversion rate among patients undergoing laparoscopic surgery for rectal cancer. METHODS We performed a retrospective secondary analysis of data collected from patients undergoing laparoscopic surgery for cStage II and III rectal cancer from 2014 to 2016 across 56 institutions affiliated with the Japan Society of Laparoscopic Colorectal Surgery. Data from the original EnSSURE study were analyzed to investigate risk factors for conversion to laparotomy by performing univariate and multivariate analyses based on the reason for conversion. RESULTS Data were collected for 3,168 cases, including 65 (2.1%) involving conversion to laparotomy. Indicated conversion accounted for 27 cases (0.9%), while technical conversion accounted for 35 cases (1.1%). The multivariate analysis identified the following independent risk factors for indicated conversion to laparotomy: tumor diameter [mm] (odds ratio [OR] 1.01, 95% confidence interval [CI] 1.01-1.05, p = 0.0002), combined resection of adjacent organs [+/-] (OR 7.92, 95% CI 3.14-19.97, p < 0.0001), and surgical participation of an ESSQS-certified physician [-/+] (OR 4.46, 95% CI 2.01-9.90, p = 0.0002). The multivariate analysis identified the following risk factors for technical conversion to laparotomy: registered case number of institution (OR 0.99, 95% CI 0.99-1.00, p = 0.0029), institution type [non-university/university hospital] (OR 3.52, 95% CI 1.54-8.04, p = 0.0028), combined resection of adjacent organs [+/-] (OR 5.96, 95% CI 2.15-16.53, p = 0.0006), and surgical participation of an ESSQS-certified physician [-/+] (OR 6.26, 95% CI 3.01-13.05, p < 0.0001). CONCLUSIONS Participation of ESSQS-certified physicians may reduce the risk of both indicated and technical conversion. Referral to specialized institutions, such as high-volume centers and university hospitals, especially for patients exhibiting relevant background risk factors, may reduce the risk of conversion to laparotomy and lead to better outcomes for patients. TRIAL REGISTRATION This study was registered with the Japanese Clinical Trials Registry as UMIN000040645.
Collapse
Affiliation(s)
- Koki Goto
- Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan
| | - Jun Watanabe
- Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan
| | - Toshiya Nagasaki
- Department of Gastroenterological Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - Mamoru Uemura
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan
| | - Heita Ozawa
- Department of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Japan
| | - Yohei Kurose
- Department of Surgery, Fukuyama City Hospital, Fukuyama, Japan
| | - Tomonori Akagi
- Department of Gastroenterological and Pediatric Surgery, Oita University, Oita, Japan.
| | - Nobuki Ichikawa
- Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Hiroaki Iijima
- Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Masafumi Inomata
- Department of Gastroenterological and Pediatric Surgery, Oita University, Oita, Japan
| | - Akinobu Taketomi
- Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Takeshi Naitoh
- Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Japan
| |
Collapse
|
3
|
Sekiguchi M, Kishida Y, Ikematsu H, Konno M, Mizuguchi Y, Hotta K, Imai K, Ito S, Takada K, Shiomi A, Yasui H, Tsukamoto S, Hirano H, Kobayashi N, Saito Y, Inaba A, Shinmura K, Konishi J, Ozawa H, Fujita S, Murakami Y, Matsuda T. Proportions and characteristics of interval cancer in annual fecal immunochemical test screening and postcolonoscopy colorectal cancer: Results from a Japanese multicenter prospective study using questionnaires, the C-DETECT study. Dig Endosc 2024. [PMID: 38433322 DOI: 10.1111/den.14772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Accepted: 01/28/2024] [Indexed: 03/05/2024]
Abstract
OBJECTIVES There are several types of colorectal cancer (CRC) according to the detection methods and intervals, including interval CRC (iCRC) and postcolonoscopy CRC (PCCRC). We aimed to examine their proportions and characteristics. METHODS We conducted a multicenter prospective study using questionnaires in Japan ("C-DETECT study"), in which differences in CRC characteristics according to detection methods and intervals were examined from consecutive adult patients. Because the annual fecal immunochemical test (FIT) was used in population-based screening, the annual FIT-iCRC was assessed. RESULTS In total, 1241 CRC patients (1064 with invasive CRC) were included. Annual FIT-iCRC (a), 3-year PCCRC (b), and CRC detected within 1 year after a positive FIT with noncompliance to colonoscopy (c) accounted for 4.5%, 7.0%, and 3.9% of all CRCs, respectively, and for 3.9%, 5.4%, and 4.3% of invasive CRCs, respectively. The comparison among these (a, b, c) and other CRCs (d) demonstrated differences in the proportions of ≥T2 invasion ([a] 58.9%, [b] 44.8%, [c] 87.5%, [d] 73.0%), metastasis ([a] 33.9%, [b] 21.8%, [c] 54.2%, [d] 43.9%), right-sided CRC ([a] 42.9%, [b] 40.2%, [c] 18.8%, [d] 28.6%), and female sex ([a] 53.6%, [b] 49.4%, [c] 27.1%, [d] 41.6%). In metastatic CRC, (a) and (b) showed a higher proportions of BRAF mutations ([a] [b] 12.0%, [c] [d] 3.1%). CONCLUSIONS Annual FIT-iCRC and 3-year PCCRC existed in nonnegligible proportions. They were characterized by higher proportions of right-sided tumors, female sex, and BRAF mutations. These findings suggest that annual FIT-iCRC and 3-year PCCRC may have biological features different from those of other CRCs.
Collapse
Affiliation(s)
- Masau Sekiguchi
- Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan
- Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan
- Division of Screening Technology, National Cancer Center Institute for Cancer Control, Tokyo, Japan
| | | | - Hiroaki Ikematsu
- Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Chiba, Japan
| | - Maki Konno
- Department of Gastroenterology, Tochigi Cancer Center, Tochigi, Japan
| | | | - Kinichi Hotta
- Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan
| | - Kenichiro Imai
- Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan
| | - Sayo Ito
- Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan
| | - Kazunori Takada
- Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan
| | - Akio Shiomi
- Division of Colorectal Surgery, Shizuoka Cancer Center, Shizuoka, Japan
| | - Hirofumi Yasui
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
| | - Shunsuke Tsukamoto
- Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan
| | - Hidekazu Hirano
- Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Nozomu Kobayashi
- Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan
- Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan
- Division of Screening Technology, National Cancer Center Institute for Cancer Control, Tokyo, Japan
| | - Yutaka Saito
- Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan
| | - Atsushi Inaba
- Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Chiba, Japan
| | - Kensuke Shinmura
- Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Chiba, Japan
| | - Jun Konishi
- Department of Gastroenterology, Tochigi Cancer Center, Tochigi, Japan
| | - Heita Ozawa
- Department of Surgery, Tochigi Cancer Center, Tochigi, Japan
| | - Shin Fujita
- Department of Surgery, Tochigi Cancer Center, Tochigi, Japan
| | | | - Takahisa Matsuda
- Division of Gastroenterology and Hepatology, Toho University Omori Medical Center, Tokyo, Japan
| |
Collapse
|
4
|
Kagawa H, Kinugasa Y, Yamaguchi T, Ohue M, Kawai K, Hiro J, Shinji S, Nozawa H, Hirano Y, Komori K, Takii Y, Suto T, Tsukamoto S, Akagi Y, Ozawa H, Toiyama Y, Minami K, Shimizu T, Uehara K, Sakamoto K, Mori K, Sugihara K, Ajioka Y. Impact of resection for ovarian metastases from colorectal cancer and clinicopathologic analysis: A multicenter retrospective study in Japan. Ann Gastroenterol Surg 2024; 8:273-283. [PMID: 38455487 PMCID: PMC10914693 DOI: 10.1002/ags3.12740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 08/17/2023] [Accepted: 08/30/2023] [Indexed: 03/09/2024] Open
Abstract
Aim The aim of this study was to clarify the significance of resection of ovarian metastases from colorectal cancer and to identify the clinicopathologic characteristics. Methods In this multicenter retrospective study, we evaluated data on ovarian metastases from colorectal cancer obtained from patients at 20 centers in Japan between 2000 and 2014. We examined the impact of resection on the prognosis of patients with ovarian metastases and examined prognostic factors. Results The study included 296 patients with ovarian metastasis. The 3-y overall survival rate was 68.6% for solitary ovarian metastases. In all cases of this cohort, the 3-y overall survival rates after curative resection, noncurative resection, and nonresection were 65.9%, 31.8%, and 6.1%, respectively (curative resection vs noncurative resection [P < 0.01] and noncurative resection vs nonresection [P < 0.01]). In the multivariate analysis of prognostic factors, tumor size of ovarian metastasis (P < 0.01), bilateral ovarian metastasis (P = 0.01), peritoneal metastasis (P < 0.01), pulmonary metastasis (P = 0.04), liver metastasis (P < 0.01), and remnant of ovarian metastasis (P < 0.01) were statistically significantly different. Conclusion The prognosis after curative resection for solitary ovarian metastases was shown to be relatively favorable as Stage IV colorectal cancer. Resection of ovarian metastases, not only curative resection but also noncurative resection, confers a survival benefit. Prognostic factors were large ovarian metastases, bilateral ovarian metastases, the presence of extraovarian metastases, and remnant ovarian metastases.
Collapse
|
5
|
Hoshino N, Hida K, Fujita Y, Ohira M, Ozawa H, Bando H, Akagi T, Kono Y, Nakajima K, Kojima Y, Nakamura T, Inomata M, Yamamoto S, Sakai Y, Naitoh T, Watanabe M, Obama K. Impact of laparoscopic surgery on short-term and long-term outcomes in elderly obese patients with colon cancer. Ann Gastroenterol Surg 2023; 7:757-764. [PMID: 37663960 PMCID: PMC10472405 DOI: 10.1002/ags3.12678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/01/2022] [Revised: 02/15/2023] [Accepted: 04/03/2023] [Indexed: 09/05/2023] Open
Abstract
Background Laparoscopic surgery is reported to be useful in obese or elderly patients with colon cancer, who are at increased risk of postoperative complications because of comorbidities and physical decline. However, its usefulness is less clear in patients who are both elderly and obese and may be at high risk of complications. Methods Data for obese patients (body mass index ≥25) who underwent laparoscopic or open surgery for stage II or III colon cancer between January 2009 and December 2013 were collected by the Japan Society of Laparoscopic Colorectal Surgery. Surgical outcomes, postoperative complications, and relapse-free survival (RFS) were compared between patients who underwent open surgery and those who underwent laparoscopic surgery according to whether they were elderly (≥70 y) or nonelderly (<70 y). Results Data of 1549 patients (elderly, n = 598; nonelderly, n = 951) satisfied the selection criteria for analysis. Length of stay was shorter and surgical wound infection was less common in elderly obese patients who underwent laparoscopic surgery than in those underwent open surgery. There were no significant between-group differences in overall complications, anastomotic leakage, ileus/small bowel obstruction, or RFS. There were also no significant differences in RFS after laparoscopic surgery according to patient age. Conclusion Laparoscopic surgery is safe in elderly obese patients with colon cancer and does not worsen their prognosis. There was no significant difference in the effectiveness of laparoscopic surgery between obese patients who were elderly and those who were nonelderly.
Collapse
Affiliation(s)
- Nobuaki Hoshino
- Department of SurgeryKyoto University Graduate School of MedicineKyotoJapan
| | - Koya Hida
- Department of SurgeryKyoto University Graduate School of MedicineKyotoJapan
| | - Yusuke Fujita
- Department of SurgeryKyoto University Graduate School of MedicineKyotoJapan
| | | | - Heita Ozawa
- Department of Colorectal SurgeryTochigi Cancer CenterUtsunomiyaJapan
| | - Hiroyuki Bando
- Department of Gastroenterological SurgeryIshikawa Prefectural Central HospitalKanazawaJapan
| | - Tomonori Akagi
- Department of Gastroenterological and Pediatric SurgeryOita University Faculty of MedicineYufuJapan
| | - Yohei Kono
- Department of Gastroenterological and Pediatric SurgeryOita University Faculty of MedicineYufuJapan
| | | | - Yutaka Kojima
- Department of Coloproctological SurgeryJuntendo University Faculty of MedicineBunkyo‐kuJapan
| | - Takatoshi Nakamura
- Department of Surgical OncologyDokkyo Medical University Graduate School of MedicineShimotsuga‐gunJapan
| | - Masafumi Inomata
- Department of Gastroenterological and Pediatric SurgeryOita University Faculty of MedicineYufuJapan
| | - Seiichiro Yamamoto
- Department of Gastroenterological SurgeryTokai University School of MedicineShibuya CityJapan
| | | | - Takeshi Naitoh
- Department of Lower Gastrointestinal SurgeryKitasato University School of MedicineSagamiharaJapan
| | | | - Kazutaka Obama
- Department of SurgeryKyoto University Graduate School of MedicineKyotoJapan
| |
Collapse
|
6
|
Kobayashi H, Kotake K, Kawasaki M, Kanemitsu Y, Kinugasa Y, Ueno H, Maeda K, Suto T, Itabashi M, Funahashi K, Ozawa H, Koyama F, Noura S, Ishida H, Ohue M, Kiyomatsu T, Ishihara S, Koda K, Baba H, Kawada K, Hashiguchi Y, Goi T, Toiyama Y, Tomita N, Sunami E, Akagi Y, Watanabe J, Hakamada K, Nakayama G, Sugihara K, Ajioka Y. A proposed new Japanese classification of synchronous peritoneal metastases from colorectal cancer: A multi-institutional, prospective, observational study conducted by the Japanese Society for Cancer of the Colon and Rectum. Ann Gastroenterol Surg 2023; 7:765-771. [PMID: 37663965 PMCID: PMC10472395 DOI: 10.1002/ags3.12679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/16/2023] [Revised: 03/20/2023] [Accepted: 04/07/2023] [Indexed: 09/05/2023] Open
Abstract
Aim To establish a new Japanese classification of synchronous peritoneal metastases from colorectal cancer. Methods This multi-institutional, prospective, observational study enrolled patients who underwent surgery for colorectal cancer with synchronous peritoneal metastases. Overall survival rates were compared according to the various models using objective indicators. Each model was evaluated by Akaike's information criterion (AIC). The region of peritoneal metastases was evaluated by the peritoneal cancer index (PCI). Results Between October 2012 and December 2016, 150 patients were enrolled. The AIC of the present Japanese classification was 1020.7. P1 metastasis was defined as confined to two regions. The minimum AIC was obtained with the cutoff number of 10 or less for P2 metastasis and 11 or more for P3 metastasis. As for size, the best discrimination ability between P2 and P3 metastasis was obtained with a cutoff value of 3 cm. The AIC of the proposed classification was 1014.7. The classification was as follows: P0, no peritoneal metastases; P1, metastases localized to adjacent peritoneum (within two regions of PCI); P2, metastases to distant peritoneum, number ≤10 and size ≤3 cm; P3, metastases to distant peritoneum, number ≥11 or size >3 cm; P3a, metastases to distant peritoneum, number ≥11 and size ≤3 cm, or number ≤10 and size >3 cm; P3b, metastases to distant peritoneum, number ≥11 and size >3 cm. Conclusion This objective classification could improve the ability to discriminate prognosis in patients with synchronous peritoneal metastases from colorectal cancer.
Collapse
Affiliation(s)
- Hirotoshi Kobayashi
- Department of SurgeryTokyo Metropolitan Hiroo HospitalTokyoJapan
- Department of SurgeryTeikyo University HospitalMizonokuchiKanagawaJapan
| | | | | | - Yukihide Kanemitsu
- Department of Colorectal SurgeryNational Cancer Center HospitalTokyoJapan
| | - Yusuke Kinugasa
- Department of Gastrointestinal SurgeryTokyo Medical and Dental UniversityTokyoJapan
| | - Hideki Ueno
- Department of SurgeryNational Defense Medical CollegeTokorozawaJapan
| | - Kotaro Maeda
- International Medical CenterFujita Health University HospitalToyoakeJapan
| | - Takeshi Suto
- Department of Gastroenterological SurgeryYamagata Prefectural Central HospitalYamagataJapan
| | - Michio Itabashi
- Department of SurgeryInstitute of Gastroenterology, Tokyo Women's Medical UniversityTokyoJapan
| | - Kimihiko Funahashi
- Department of General and Gastroenterological SurgeryToho University Omori Medical CenterTokyoJapan
| | - Heita Ozawa
- Department of SurgeryTochigi Cancer CenterUtsunomiyaJapan
| | | | - Shingo Noura
- Department of SurgeryOsaka Rosai HospitalSakaiJapan
| | - Hideyuki Ishida
- Department of Digestive Tract and General SurgerySaitama Medical Center, Saitama Medical UniversityKawagoeJapan
| | - Masayuki Ohue
- Department of Gastroenterological SurgeryOsaka International Cancer InstituteOsakaJapan
| | - Tomomichi Kiyomatsu
- Department of Colorectal SurgeryNational Center for Global Health and MedicineTokyoJapan
| | - Soichiro Ishihara
- Department of Surgical OncologyThe University of Tokyo HospitalTokyoJapan
| | - Keiji Koda
- Department of SurgeryTeikyo University Chiba Medical CenterIchihara CityChibaJapan
| | - Hideo Baba
- Department of Gastroenterological SurgeryGraduate School of Medical Sciences, Kumamoto UniversityKumamotoJapan
| | - Kenji Kawada
- Department of Gastrointestinal SurgeryGraduate School of Medicine, Kyoto UniversityKyotoJapan
| | | | - Takanori Goi
- First Department of SurgeryUniversity of FukuiFukuiJapan
| | - Yuji Toiyama
- Division of Reparative Medicine, Department of Gastrointestinal and Pediatric Surgery, Institute of Life SciencesMie University Graduate School of MedicineTsuMieJapan
| | - Naohiro Tomita
- Division of Lower Gastrointestinal Surgery, Department of Gastroenterological SurgeryHyogo Medical UniversityNishinomiyaHyogoJapan
| | - Eiji Sunami
- Department of SurgeryKyorin University School of MedicineTokyoJapan
| | - Yoshito Akagi
- Department of SurgeryKurume University School of MedicineKurumeJapan
| | - Jun Watanabe
- Department of SurgeryGastroenterological Center, Yokohama City University Medical CenterYokohamaJapan
| | - Kenichi Hakamada
- Department of Gastroenterological SurgeryHirosaki University Graduate School of MedicineAomoriJapan
| | - Goro Nakayama
- Department of Gastroenterological Surgery (Surgery II)Nagoya University Graduate School of MedicineNagoyaJapan
| | | | - Yoichi Ajioka
- Division of Molecular and Diagnostic Pathology, Graduate School of Medical and Dental SciencesNiigata UniversityNiigataJapan
| |
Collapse
|
7
|
Shinto E, Oki E, Shimokawa M, Yamaguchi S, Ishiguro M, Hasegawa S, Takii Y, Ishida H, Kusumoto T, Morita M, Tomita N, Shiozawa M, Tanaka M, Ozawa H, Hashiguchi Y, Ohnuma S, Tada S, Matsushima T, Yamagishi K, Hase K. Enhanced Clinical Utility of Molecular Budding Signature as a Recurrence Risk Determinant in Stage II and III Colon Cancer Patients. Ann Surg Oncol 2023; 30:5239-5247. [PMID: 37154970 DOI: 10.1245/s10434-023-13594-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Accepted: 04/17/2023] [Indexed: 05/10/2023]
Abstract
BACKGROUND A molecular budding signature (MBS), which consists of seven tumor budding-related genes, was recently presented as a prominent prognostic indicator in colon cancer (CC) using microarray data acquired from frozen specimens. This study aimed to confirm the predictive power of MBS for recurrence risk based on formalin-fixed, paraffin-embedded (FFPE) materials. METHODS This research utilized the same microarray data from a prior multicenter study using FFPE whole tissue sections, which retrospectively reviewed 232 stage II CC patients without adjuvant chemotherapy and 302 stage III CC patients with adjuvant chemotherapy. All patients underwent upfront curative surgery without neoadjuvant therapy between 2009 and 2012. An MBS score was calculated using the mean of log2 [each signal] of seven genes (MSLN, SLC4A11, WNT11, SCEL, RUNX2, MGAT3, and FOXC1) as described before. RESULTS The MBS-low group exhibited a better relapse-free survival (RFS) than the MBS-high group in stage II (P = 0.0077) and in stage III CC patients (P = 0.0003). Multivariate analyses revealed that the MBS score was an independent prognostic factor in both stage II (P = 0.0257) and stage III patients (P = 0.0022). Especially among T4, N2, or both (high-risk) stage III patients, the MBS-low group demonstrated markedly better RFS compared with the MBS-high group (P = 0.0013). CONCLUSIONS This study confirmed the predictive power of the MBS for recurrence risk by employing FFPE materials in stage II/III CC patients.
Collapse
Affiliation(s)
- Eiji Shinto
- Department of Surgery, National Defense Medical College, Tokorozawa, Japan.
| | - Eiji Oki
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Mototsugu Shimokawa
- Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - Shigeki Yamaguchi
- Department of Surgery, Division of Colorectal Surgery, Tokyo Women's Medical University, Tokyo, Japan
| | - Megumi Ishiguro
- Medical Innovation Promotion Center, Tokyo Medical and Dental University, Tokyo, Japan
| | - Seiji Hasegawa
- Department of Surgery, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan
| | - Yasumasa Takii
- Department of Gastroenterological Surgery, Niigata Cancer Center Hospital, Niigata, Japan
| | - Hideyuki Ishida
- Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
| | - Tetsuya Kusumoto
- Department of Gastroenterological Surgery, Clinical Research Center, Cancer Research Division, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
| | - Masaru Morita
- Department of Gastroenterological Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
| | - Naohiro Tomita
- Cancer Treatment Center, Toyonaka Municipal Hospital, Toyonaka, Japan
| | - Manabu Shiozawa
- Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan
| | | | - Heita Ozawa
- Department of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Japan
| | - Yojiro Hashiguchi
- Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan
| | - Shinobu Ohnuma
- Department of Surgery, Tohoku University Hospital, Sendai, Japan
| | | | | | | | - Kazuo Hase
- Department of Surgery, National Defense Medical College, Tokorozawa, Japan
| |
Collapse
|
8
|
Shinto E, Oki E, Shimokawa M, Yamaguchi S, Ishiguro M, Hasegawa S, Takii Y, Ishida H, Kusumoto T, Morita M, Tomita N, Shiozawa M, Tanaka M, Ozawa H, Hashiguchi Y, Ohnuma S, Tada S, Matsushima T, Yamagishi K, Hase K. ASO Visual Abstract: Enhanced Clinical Utility of Molecular Budding Signature as a Recurrence Risk Determinant in Stage II and III Colon Cancer Patients. Ann Surg Oncol 2023; 30:5250-5251. [PMID: 37266811 DOI: 10.1245/s10434-023-13684-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Affiliation(s)
- Eiji Shinto
- Department of Surgery, National Defense Medical College, Tokorozawa, Saitama, Japan.
| | - Eiji Oki
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Mototsugu Shimokawa
- Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - Shigeki Yamaguchi
- Department of Surgery, Division of Colorectal Surgery, Tokyo Women's Medical University, Tokyo, Japan
| | - Megumi Ishiguro
- Medical Innovation Promotion Center, Tokyo Medical and Dental University, Tokyo, Japan
| | - Seiji Hasegawa
- Department of Surgery, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan
| | - Yasumasa Takii
- Department of Gastroenterological Surgery, Niigata Cancer Center Hospital, Niigata, Japan
| | - Hideyuki Ishida
- Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
| | - Tetsuya Kusumoto
- Department of Gastroenterological Surgery, Clinical Research Center, Cancer Research Division, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
| | - Masaru Morita
- Department of Gastroenterological Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
| | - Naohiro Tomita
- Cancer Treatment Center, Toyonaka Municipal Hospital, Toyonaka, Japan
| | - Manabu Shiozawa
- Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan
| | | | - Heita Ozawa
- Department of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Japan
| | - Yojiro Hashiguchi
- Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan
| | - Shinobu Ohnuma
- Department of Surgery, Tohoku University Hospital, Sendai, Japan
| | | | | | | | - Kazuo Hase
- Department of Surgery, National Defense Medical College, Tokorozawa, Saitama, Japan
| |
Collapse
|
9
|
Ueno H, Hase K, Shiomi A, Shiozawa M, Ito M, Sato T, Hashiguchi Y, Kusumi T, Kinugasa Y, Ike H, Matsuda K, Yamada K, Komori K, Takahashi K, Kanemitsu Y, Ozawa H, Ohue M, Masaki T, Takii Y, Ishibe A, Watanabe J, Toiyama Y, Sonoda H, Koda K, Akagi Y, Itabashi M, Nakamura T, Sugihara K. Optimal bowel resection margin in colon cancer surgery: prospective multicentre cohort study with lymph node and feeding artery mapping. Lancet Reg Health West Pac 2023; 33:100680. [PMID: 37181532 PMCID: PMC10166781 DOI: 10.1016/j.lanwpc.2022.100680] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2022] [Revised: 12/13/2022] [Accepted: 12/21/2022] [Indexed: 01/20/2023]
Abstract
Background There are no standardised criteria for the 'regional' pericolic node in colon cancer, which represents a major cause of the international uncertainty regarding the optimal bowel resection margin. This study aimed to determine 'regional' pericolic nodes based on prospective lymph node (LN) mapping. Methods According to preplanned in vivo measurements of the bowel, the anatomical distributions of the feeding artery and LNs were determined in 2996 stages I-III colon cancer patients who underwent colectomy with resection margin >10 cm at 25 institutions in Japan. Findings The mean number of retrieved pericolic nodes was 20.9 (standard deviation, 10.8) per patient. In all patients except seven (0.2%), the primary feeding artery was distributed within 10 cm of the primary tumour. The metastatic pericolic node most distant from the primary tumour was within 3 cm in 837 patients, 3-5 cm in 130 patients, 5-7 cm in 39 patients and 7-10 cm in 34 patients. Only four patients (0.1%) had pericolic lymphatic spread beyond 10 cm; all of whom had T3/4 tumours accompanying extensive mesenteric lymphatic spread. The location of metastatic pericolic node did not differ by the feeding artery's distribution. Postoperatively, none of the 2996 patients developed recurrence in the remaining pericolic nodes. Interpretation The pericolic nodes designated as 'regional' were those located within 10 cm of the primary tumours, which should be fully considered when determining the bowel resection margin, even in the era of complete mesocolic excision. Funding Japanese Society for Cancer of the Colon and Rectum.
Collapse
Affiliation(s)
- Hideki Ueno
- Department of Surgery, National Defense Medical College, Saitama, Japan
| | - Kazuo Hase
- Department of Surgery, National Defense Medical College, Saitama, Japan
| | - Akio Shiomi
- Division of Colorectal Surgery, Shizuoka Cancer Center Hospital, Shizuoka, Japan
| | - Manabu Shiozawa
- Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Kanagawa, Japan
| | - Masaaki Ito
- Colorectal and Pelvic Surgery Division, Department of Surgical Oncology, National Cancer Center Hospital East, Chiba, Japan
| | - Toshihiko Sato
- Department of Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan
| | - Yojiro Hashiguchi
- Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan
| | - Takaya Kusumi
- Department of Surgery, Keiyukai Sappro Hospital, Hokkaido, Japan
| | - Yusuke Kinugasa
- Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo, Japan
| | - Hideyuki Ike
- Department of Surgery, Saisei-kai Yokohama-shi Nanbu Hospital, Kanagawa, Japan
| | - Kenji Matsuda
- Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan
| | - Kazutaka Yamada
- Department of Gastroenterological Surgery, Coloproctology Center, Takano Hospital, Kumamoto, Japan
| | - Koji Komori
- Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Aichi, Japan
| | - Keiichi Takahashi
- Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
| | - Yukihide Kanemitsu
- Department of Colorectal Surgery, National Cancer Centre Hospital, Tokyo, Japan
| | - Heita Ozawa
- Department of Surgery, Tochigi Cancer Centre, Utsunomiya, Japan
| | - Masayuki Ohue
- Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan
| | - Tadahiko Masaki
- Department of Surgery, Kyorin University School of Medicine, Tokyo, Japan
| | - Yasumasa Takii
- Department of Surgery, Niigata Cancer Centre Hospital, Niigata, Japan
| | - Atsushi Ishibe
- Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Kanagawa, Japan
| | - Jun Watanabe
- Department of Surgery, Gastroenterological Centre, Yokohama City University Medical Centre, Kanagawa, Japan
| | - Yuji Toiyama
- Department of Gastrointestinal and Pediatric Surgery, Mie University Graduate School of Medicine, Mie, Japan
| | - Hiromichi Sonoda
- Department of Surgery, Shiga University of Medical Science, Shiga, Japan
| | - Keiji Koda
- Department of Surgery, Teikyo University Chiba Medical Centre, Chiba, Japan
| | - Yoshito Akagi
- Department of Surgery, Kurume University School of Medicine, Fukuoka, Japan
| | - Michio Itabashi
- Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan
| | - Takahiro Nakamura
- Laboratory for Mathematics, National Defense Medical College, Saitama, Japan
| | | |
Collapse
|
10
|
Ozawa H, Toyota N, Sakamoto J, Nakanishi H, Nakanishi R, Fujita S. Mid-term outcomes of intracorporeal versus extracorporeal anastomosis after laparoscopic colectomy: a propensity score-matched cohort study from a single institution. Surg Today 2023:10.1007/s00595-022-02636-y. [PMID: 36656391 DOI: 10.1007/s00595-022-02636-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2022] [Accepted: 12/15/2022] [Indexed: 01/20/2023]
Abstract
PURPOSE There is still insufficient discussion of the mid- to long-term safety of the intracorporeal anastomosis (IA) method of reconstruction after laparoscopic colectomy (LAC) for colon cancer. The present study clarified the postoperative mid-term results of IA based on recurrence and the incidence of incision hernia. METHODS This single-institution observational retrospective study included 268 patients with colon cancer who underwent IA or extracorporeal anastomosis (EA) after LAC at our institution between 2018 and 2021. The mid-term results of the IA group were compared with those of the EA group using a propensity score matching method. RESULTS The median follow-up periods were 36 and 25 months in the EA and IA groups, respectively (p < 0.0001). In this matched cohort study, the recurrence-free survival (RFS) rates were comparable between the IA and EA groups (each group, n = 72; 3-year RFS: IA, 92.1%; EA, 88.2%; hazard ratio, 0.78; 95% confidence interval, 0.25-2.40; p = 0.66). The cumulative incisional hernia rates were 9.8% and 9.9% (p = 0.99) for the IA and EA groups, respectively. CONCLUSION The safety of IA after LAC was demonstrated in this study, as IA after LAC showed good mid-term results, including with regard to the rates of recurrence and incisional hernia.
Collapse
Affiliation(s)
- Heita Ozawa
- Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan.
| | - Naoyuki Toyota
- Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan
| | - Junichi Sakamoto
- Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan
| | - Hiroki Nakanishi
- Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan
| | - Ryo Nakanishi
- Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan
| | - Shin Fujita
- Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan
| |
Collapse
|
11
|
Sato H, Maeda K, Kinugasa Y, Kagawa H, Tsukamoto S, Takahashi K, Nozawa H, Takii Y, Konishi T, Akagi Y, Suto T, Yamaguchi S, Ozawa H, Komori K, Ohue M, Hiro J, Shinji S, Minami K, Shimizu T, Sakamoto K, Uehara K, Takahashi H, Sugihara K. Management of inguinal lymph node metastases from rectal and anal canal adenocarcinoma. Colorectal Dis 2022; 24:1150-1163. [PMID: 35505622 DOI: 10.1111/codi.16169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 04/13/2022] [Accepted: 04/18/2022] [Indexed: 02/08/2023]
Abstract
AIM The surgical treatment of inguinal lymph node (ILN) metastases secondary to anorectal adenocarcinoma remains controversial. This study aimed to clarify the surgical treatment and management of ILN metastasis according to its classification. METHODS This retrospective, multi-centre, observational study included patients with synchronous or metachronous ILN metastases who were diagnosed with rectal or anal canal adenocarcinoma between January 1997 and December 2011. Treatment outcomes were analysed according to recurrence and prognosis. RESULTS Among 1181 consecutively enrolled patients who received treatment for rectal or anal canal adenocarcinoma at 20 referral hospitals, 76 (6.4%) and 65 (5.5%) had synchronous and metachronous ILN metastases, respectively. Among 141 patients with ILN metastasis, differentiated carcinoma, solitary ILN metastasis and ILN dissection were identified as independent predictive factors associated with a favourable prognosis. No significant difference was found in the frequency of recurrence after ILN dissection between patients with synchronous (80.6%) or metachronous (81.0%) ILN metastases. Patients who underwent R0 resection of the primary tumour and ILN dissection had a 5-year survival rate of 41.3% after ILN dissection (34.1% and 53.1% for patients with synchronous and metachronous ILN metastases, respectively, P = 0.55). CONCLUSION The ILN can be appropriately classified as a regional lymph node in rectal and anal canal adenocarcinoma. Moreover, aggressive ILN dissection might be effective in improving the prognosis of low rectal and anal canal adenocarcinoma with ILN metastases; thus, prophylactic ILN dissection is unnecessary.
Collapse
Affiliation(s)
- Harunobu Sato
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,Department of Surgery, Fujita Health University School of Medicine, Toyoake, Japan
| | - Kotaro Maeda
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,International Medical Center, Fujita Health University Hospital, Toyoake, Japan
| | - Yusuke Kinugasa
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo, Japan
| | - Hiroyasu Kagawa
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,Division of Colon and Rectal Surgery, Shizuoka Cancer Center, Sunto-gun, Japan
| | - Shunsuke Tsukamoto
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan
| | - Keiichi Takahashi
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.,Department of Surgery, Tokyo Metropolitan Health and Hospitals Corporation Ohkubo Hospital, Tokyo, Japan
| | - Hiroaki Nozawa
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,Department of Surgical Oncology, Faculty of Medicine, University of Tokyo, Tokyo, Japan
| | - Yasumasa Takii
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,Department of Gastroenterological Surgery, Niigata Cancer Center Hospital, Niigata, Japan
| | - Tsuyoshi Konishi
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,Department of Gastroenterological Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.,Department of Colon and Rectal Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Yoshito Akagi
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,Department of Surgery, Kurume University School of Medicine, Kurume, Japan
| | - Takeshi Suto
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,Department of Gastroenterological Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan
| | - Shigeki Yamaguchi
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,Department of Colorectal Surgery, Saitama Medical University International Medical Center, Saitama, Japan.,Division of Colorectal Surgery, Department of Surgery, Tokyo Women's Medical University, Tokyo, Japan
| | - Heita Ozawa
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,Department of Surgery, Tochigi Cancer Center, Tochigi, Japan
| | - Koji Komori
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Masayuki Ohue
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan
| | - Junichiro Hiro
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,Department of Surgery, Fujita Health University School of Medicine, Toyoake, Japan.,Division of Reparative Medicine, Department of Gastrointestinal and Pediatric Surgery, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu, Japan
| | - Seiichi Shinji
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,Department of Gastrointestinal Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan
| | - Kazuhito Minami
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,Department of Surgery, Matsuyama Red Cross Hospital, Matsuyama, Japan
| | - Tomoharu Shimizu
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,Division of Medical Safety Section, Shiga University of Medical Science, Otsu, Japan
| | - Kazuhiro Sakamoto
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,Department of Coloproctological Surgery, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Kay Uehara
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Hiroshi Takahashi
- Department of Medical Statistics, Fujita Health University School of Medicine, Toyoake, Japan
| | - Kenichi Sugihara
- Study Group for Inguinal Lymph Node Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.,Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo, Japan
| |
Collapse
|
12
|
Sakamoto J, Toyota N, Nakanishi H, Ozawa H, Fujita S. [Usefulness of Nutritional Evaluation in Adjuvant Chemotherapy for Colorectal Cancer in Older Patients]. Gan To Kagaku Ryoho 2022; 49:1087-1091. [PMID: 36281600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
OBJECTIVE To clarify the usefulness of Onodera's prognostic nutritional index(OPNI)in adjuvant chemotherapy(AC)for older patients with colorectal cancer. MATERIALS AND METHODS This study included 39 patients aged over 70 years who underwent AC for colorectal cancer from August 2009 to February 2018. We evaluated the association of OPNI with AC toxicities and prognosis. RESULTS OPNI was an independent predictor of toxicities of Grade 3 or higher(OR: 0.18, 95%CI: 0.043-0.75, p=0.019). The 3-year recurrence-free survival rate was significantly better in the higher OPNI group than in the lower OPNI group(89.9% and 66.7%, respectively; HR: 0.19, 95%CI: 0.04-0.92, p=0.038). There was a positive correlation with Spearman's rank correlation coefficient of 0.66 in OPNI before and after AC(p<0.001). CONCLUSION OPNI could be one of the valuable predictors of AC toxicities and the prognosis. There was a high correlation between OPNI before and after AC. These findings suggest the importance of early nutritional support for patients with lower OPNI.
Collapse
|
13
|
Watanabe J, Kanemitsu Y, Suwa H, Kakeji Y, Ishihara S, Shinto E, Ozawa H, Suto T, Kawamura J, Fujita F, Itabashi M, Ohue M, Ike H, Sugihara K. A multicenter cohort study on mapping of lymph node metastasis for splenic flexural colon cancer. Ann Gastroenterol Surg 2022; 7:265-271. [PMID: 36998296 PMCID: PMC10043763 DOI: 10.1002/ags3.12620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2022] [Accepted: 09/01/2022] [Indexed: 04/01/2023] Open
Abstract
Aim There have been no reports of searching for metastases to lymph nodes along the accessory middle colic artery (aMCA). The aim of this study was to investigate the metastasis rate of the aMCA for splenic flexural colon cancer. Methods Patients with histologically proven colon carcinoma located in the splenic flexure, clinically diagnosed as stage I-III were eligible for this study. Patients were retrospectively and prospectively enrolled. The primary endpoint was frequency of lymph node metastasis to the aMCA (station 222-acc and 223-acc). The secondary endpoint was the frequency of lymph node metastasis to the middle colic artery (MCA) (station 222-lt and 223) and left colic artery (LCA) (station 232 and 253). Results Between January 2013 and February 2021, a total of 153 consecutive patients were enrolled. The location of the tumor was 58% in the transverse colon and 42% in the descending colon. Lymph node metastases were observed in 49 cases (32%). The presence of aMCA rate was 41.8% (64 cases). The metastasis rates of stations 221, 222-lt, and 223 were 20.0%, 1.6%, and 0%, and stations 231, 232, and 253 were 21.4%, 1.0%, and 0%, respectively. The metastasis rates of stations 222-acc and 223-acc were 6.3% (95% confidence interval: 1.7%-15.2%) and 3.7% (95% confidence interval: 0.1%-19%), respectively. Conclusions This study identified the distribution of lymph node metastases from splenic flexural colon cancer. If the aMCA is present, this vessel should be targeted for dissection, taking into account the frequency of lymph node metastasis.
Collapse
Affiliation(s)
- Jun Watanabe
- Department of Surgery, Gastroenterological CenterYokohama City University Medical CenterYokohamaJapan
| | - Yukihide Kanemitsu
- Department of Colorectal SurgeryNational Cancer Center HospitalTokyoJapan
| | - Hirokazu Suwa
- Department of SurgeryYokosuka Kyosai HospitalYokosukaJapan
| | - Yoshihiro Kakeji
- Division of Gastrointestinal Surgery, Department of SurgeryKobe University Graduate School of MedicineKobeJapan
| | - Soichiro Ishihara
- Department of Surgical Oncology, Graduate School of MedicineThe University of TokyoTokyoJapan
| | - Eiji Shinto
- Department of SurgeryNational Defense Medical CollegeTokorozawaJapan
| | - Heita Ozawa
- Department of Colorectal SurgeryTochigi Cancer CenterUtsunomiyaJapan
| | - Takeshi Suto
- Department of Gastroenterological SurgeryYamagata Prefectual Central HospitalYamagataJapan
| | - Junichiro Kawamura
- Department of SurgeryKindai University Faculty of MedicineOsakasayamaJapan
| | | | - Michio Itabashi
- Department of SurgeryInstitute of Gastroenterology, Tokyo Women's Medical UniversityTokyoJapan
| | - Masayuki Ohue
- Department of Gastroenterological SurgeryOsaka International Cancer InstituteOsakaJapan
| | - Hideyuki Ike
- Department of SurgeryJCHO Yokohama Hodogaya Central HospitalYokohamaJapan
| | | | | |
Collapse
|
14
|
Sakamoto J, Ozawa H, Nakanishi H, Toyota N, Fujita S. Laparoscopic Colectomy for a Patient with Situs Inversus Totalis: The Usefulness of Preoperative Assessment. Am J Case Rep 2022; 23:e935538. [PMID: 35869611 PMCID: PMC9326785 DOI: 10.12659/ajcr.935538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
Abstract
Patient: Female, 63-year-old
Final Diagnosis: Transverse colon cancer
Symptoms: None
Medication:—
Clinical Procedure: —
Specialty: Oncology
Collapse
Affiliation(s)
- Junichi Sakamoto
- Department of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan
| | - Heita Ozawa
- Department of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan
| | - Hiroki Nakanishi
- Department of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan
| | - Naoyuki Toyota
- Department of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan
| | - Shin Fujita
- Department of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan
| |
Collapse
|
15
|
Sakamoto J, Ozawa H, Nakanishi H, Toyota N, Fujita S. [Retrospective Analysis of Adjuvant Chemotherapy for Elderly Patients with Stage Ⅲ Colorectal Cancer]. Gan To Kagaku Ryoho 2022; 49:553-556. [PMID: 35578933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
OBJECTIVE To investigate the efficacy and toxicity of adjuvant chemotherapy(AC)in elderly patients with Stage Ⅲ colorectal cancer(CRC). METHODS We performed a single-institutional retrospective analysis of 84 patients aged≥75 years with Stage Ⅲ CRC who underwent curative resection from August 2009 to February 2018. RESULTS Thirty-seven(44.0%) patients received AC. Eleven(29.7%)patients required dose reduction at the start of AC. Twenty-three(62.2%)patients accomplished AC, and 13(35.1%)needed dose reduction during AC. Although toxicities of Grade 3 or higher occurred in 56.8% of patients, they were controllable. The 3-year recurrence-free survival rate was significantly better in the AC group than in the non-AC group(70.3% versus 50.5%, respectively; p=0.011). The prognosis tended to be worse in the group that started AC with dose reduction than in the group with the normal dose. CONCLUSION AC is effective and well tolerated in elderly patients with Stage Ⅲ CRC. When reducing the initial dose, the need for dose reduction should be carefully considered.
Collapse
|
16
|
Shinto E, Ike H, Ito M, Takahashi K, Ohue M, Kanemitsu Y, Suto T, Kinugasa T, Watanabe J, Hida JI, Itabashi M, Ozawa H, Nozawa H, Kobayashi H, Hashiguchi Y, Hase K, Sugihara K. OUP accepted manuscript. BJS Open 2022; 6:6544103. [PMID: 35257141 PMCID: PMC8902341 DOI: 10.1093/bjsopen/zrac006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2021] [Revised: 01/13/2022] [Accepted: 01/14/2022] [Indexed: 11/20/2022] Open
Abstract
Background Patients with lateral node metastasis in low rectal cancers have a poor prognosis. However, variability in patient survival in terms of lateral metastatic status has not been thoroughly investigated. This study was conducted to assess the prognostic value of lateral node involvement and to review nodal classification. Methods Patients with stage III low rectal cancers who underwent lateral node dissection were retrospectively reviewed. Two cohorts were set: the first one (1995–2006) was selected using a Japanese multi-institutional database and was used for development of a new nodal system, and the second (2007–2013) was collected from referral institutions for validation of findings. Variables correlated with poor prognosis were investigated. Next, a modified classification of lateral-positive nodal cancers was created. Finally, this new classification was compared with TNM and Japanese classification-based systems according to the Akaike information criterion (AIC) and concordance index (c-index). Results Overall, 742 and 508 patients were selected for cohorts 1 and 2, respectively. Based on the analyses on cohort 1, patients with two or more lateral metastatic nodes partially spreading into regions outside of internal iliac area exhibited poor prognosis; accordingly, a modified N classification was created, where TNM-N1 and N2a cancers with this feature were upgraded, respectively, to N2a and N2b. The modified N classification yielded the most favourable indices (AIC = 2661.08; c-index = 0.6477) compared with the TNM (AIC = 2662.36; c-index = 0.6457) and Japanese classification-based systems (AIC = 2684.06; c-index = 0.6302). All findings were confirmed by analysing cohort 2. Conclusion A modified nodal system is proposed to account for the significance of lateral node metastasis.
Collapse
Affiliation(s)
- Eiji Shinto
- Correspondence to: Eiji Shinto, Department of Surgery National Defense Medical College 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan (e-mail: )
| | - Hideyuki Ike
- Department of Surgery, JCHO Yokohama Hodogaya Central Hospital, Yokohama, Japan
| | - Masaaki Ito
- Department of Colorectal Surgery, National Cancer Center Hospital East, Kashiwa, Japan
| | - Keiichi Takahashi
- Department of Surgery, Tokyo Metropolitan Health and Hospitals Corporation Ohkubo Hospital, Tokyo, Japan
| | - Masayuki Ohue
- Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan
| | - Yukihide Kanemitsu
- Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan
| | - Takeshi Suto
- Department of Gastroenterological Surgery, Yamagata Prefectual Central Hospital, Yamagata, Japan
| | | | - Jun Watanabe
- Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan
| | - Jin-ichi Hida
- Department of Surgery, Kindai University Nara Hospital, Ikoma, Japan
| | - Michio Itabashi
- Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan
| | - Heita Ozawa
- Department of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Japan
| | - Hiroaki Nozawa
- Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan
| | - Hirotoshi Kobayashi
- Department of Surgery, Teikyo University Hospital, Mizonokuchi, Kawasaki, Japan
| | - Yojiro Hashiguchi
- Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan
| | - Kazuo Hase
- Department of Surgery, National Defense Medical College, Tokorozawa, Japan
| | | |
Collapse
|
17
|
Sakamoto J, Ozawa H, Nakanishi H, Fujita S. Usefulness of Carcinoembryonic Antigen Doubling Time in Prognosis Prediction after Curative Resection of Locally Recurrent Rectal Cancer: A Retrospective Study. Dig Surg 2021; 39:17-23. [PMID: 34749370 DOI: 10.1159/000520694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/10/2021] [Accepted: 11/03/2021] [Indexed: 12/10/2022]
Abstract
INTRODUCTION Given that doubling time is an indicator of tumor growth, we assessed the usefulness of carcinoembryonic antigen doubling time (CEA-DT) in prognosis prediction after curative resection for locally recurrent rectal cancer. METHODS During January 1986-December 2016, 33 patients with locally recurrent rectal cancer who underwent curative resection at our hospital were retrospectively reviewed. The primary endpoint was the 3-year recurrence-free survival (RFS) rate. The Kaplan-Meier method was used to compare RFS rates and evaluate univariate and multivariate analyses for factors associated with oncologic outcomes, including CEA-DT. CEA-DT was classified into 2 groups: the short and long CEA-DT groups. RESULTS The 3-year overall survival and RFS rates were 62.6% and 42.4%, respectively. In multivariate analyses, CEA-DT was an independent risk factor for poor RFS. The 3-year RFS rate was significantly better in the long CEA-DT group than in the short CEA-DT group (58.8% vs. 25.0%, p = 0.0063). CONCLUSION CEA-DT is a useful prognostic factor that can be assessed before surgery for locally recurrent rectal cancer. Long CEA-DT may indicate a favorable prognosis. Contrarily, short CEA-DT is associated with poor prognosis; therefore, further treatment intervention is necessary for patients with short CEA-DT.
Collapse
Affiliation(s)
- Junichi Sakamoto
- Department of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan
| | - Heita Ozawa
- Department of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan
| | - Hiroki Nakanishi
- Department of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan
| | - Shin Fujita
- Department of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan
| |
Collapse
|
18
|
Ozawa H, Sakamoto J, Nakanishi H, Fujita S. Short-term outcomes of intracorporeal versus extracorporeal anastomosis after laparoscopic colectomy: a propensity score-matched cohort study from a single institution. Surg Today 2021; 52:616-623. [PMID: 34669014 DOI: 10.1007/s00595-021-02375-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Accepted: 07/18/2021] [Indexed: 01/19/2023]
Abstract
PURPOSE To compare the postoperative short-term results of intracorporeal anastomosis (IA) using overlap anastomosis (OLA), with those of extracorporeal anastomosis (EA) using functional end-to-end anastomosis (FEEA) or hand-sewn anastomosis (HSA), after laparoscopic colectomy (LAC). METHODS The subjects of this retrospective study were 208 patients with colon cancer who underwent OLA, FEEA, or HSA after LAC at our institution, between 2018 and 2021. The short-term results of the OLA group were compared with those of the FEEA and HSA groups, respectively, using a propensity score-matching method. RESULTS The mean operative time for anastomosis was longer in the OLA group than in the FEEA and HSA groups (p < 0.0001). The mean blood loss volume was less in the OLA group than in the FEEA and HSA groups (p = 0.0344 and p = 0.0002, respectively). The mean skin incision size was smaller in the OLA group than in the FEEA and HSA groups (p < 0.0001 and p = 0.0031, respectively). None of the patients in the OLA group had surgical site infections. Three to five patients were required for the surgeon to plateau on the learning curve. CONCLUSION Although IA required more time than EA, the skills appeared to improve with experience and the short-term results were superior to those of EA.
Collapse
Affiliation(s)
- Heita Ozawa
- Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan.
| | - Junichi Sakamoto
- Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan
| | - Hiroki Nakanishi
- Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan
| | - Shin Fujita
- Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan
| |
Collapse
|
19
|
Ito T, Fukui S, Kanie T, Nakai T, Kidoguchi G, Ozawa H, Kawaai S, Ikeda Y, Koido A, Haji Y, Nomura A, Tamaki H, Yamaguchi K, Okada M. AB0763 IGG4-RELATED CORONARY PERIARTERITIS: SYSTEMATIC LITERATURE REVIEW WITH OUR CASE SERIES. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Coronary periarteritis is one of the clinical manifestations of IgG4-related disease. It can cause serious conditions such as angina and ruptured aneurysms. Therefore, it is important to recognize the clinical and radiological characteristics, which was little known.Objectives:We report four patients with IgG4-related coronary periarteritis with a systematic literature review.Methods:We identified four patients with IgG4-related coronary periarteritis at the St. Luke’s International Hospital in Tokyo, Japan from 2014 to 2020. A systematic literature review was conducted for English articles on IgG4-related coronary periarteritis cases with a full text or abstract available. We summarized patient demographics, IgG and IgG4 titers, the site and morphological type of coronary lesion, and other organ involvements.Results:Our 4 cases and 38 cases identified by the literature review were assessed. Coronary artery lesions were detected by a coronary CT in all but two cases. Wall thickening was the most common type of the lesion. Moreover, there were 32 (76.1%) patients with other organ involvements. The commonest other lesion was peri-aortitis in 21 (50.0%) patients. In cases with peri-aortitis, IgG and IgG4 titers were significantly higher than those without peri-aortitis (IgG4; 1540 [705.0, 2570.0] vs 246.0 [160.0, 536.3]; p = 0.001, IgG; 3596.5 [2838.3, 4260.0] vs 1779.0 [1288.3, 1992.8]; p =0.040). In addition, 15 (71.4%) patients of them had three or more IgG4 related organ involvements.Conclusion:Coronary CT was a useful imaging modality for the diagnosis of IgG4-related coronary periarteritis, and wall thickening was the most common lesion. Moreover, about half cases coexisted with peri-aortitis. Peri-aortitis and other organ involvements should be screened in those with higher IgG and IgG4.Table 1.Characteristics of our cases and the literature review cases.RCA: right coronary artery, LAD: left anterior descending artery, LCx: left circumflex arteryDisclosure of Interests:None declared
Collapse
|
20
|
Ozawa H, Yamauchi S, Nakanishi H, Sakamoto J, Fujita S, Sugihara K. Clinical impact of non-predominant histopathological subtypes on the long-term prognosis of colorectal cancer patients in Japan. Int J Colorectal Dis 2020; 35:2257-2266. [PMID: 32772123 DOI: 10.1007/s00384-020-03707-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 07/23/2020] [Indexed: 02/04/2023]
Abstract
PURPOSE We performed a retrospective study to clarify the long-term prognosis of patients with histopathological high-grade colorectal cancer (CRC). METHODS We reviewed data from 24 institutions for 18,360 patients with pStage I to III CRC who had undergone curative surgery between 2004 and 2012. The patients were classified into seven groups according to the proportion of the histopathological component: classical adenocarcinoma (CAC) group, M-l and M-h groups (< 50% and ≥ 50% mucinous adenocarcinoma, respectively), P-l and P-h groups (< 50% and ≥ 50% poorly differentiated adenocarcinoma, respectively), and S-l and S-h groups (< 50% and ≥ 50% signet-ring cell carcinoma (SRCC), respectively). RESULTS The 5-year recurrence-free survival (RFS) rates of the M-l, P-l, and S-l groups were 75.5%, 68.4%, and 52.4%, respectively, and were significantly lower than those of the CAC group (83.5%, hazard ratio [HR] 1.22, 95% confidence interval [CI] 1.01-1.48, p = 0.0365; HR 1.60, 95% CI 1.32-1.91, p < 0.0001; HR 2.61, 95% CI 1.30-4.57, p = 0.0090, respectively). The 5-year RFS of the P-l and S-l groups was as poor as that of the P-h and S-h groups, respectively (HR 0.87, 95% CI 0.68-1.10, p = 0.25; HR 0.90, 95% CI 0.37-2.13, p = 0.81, respectively). The histopathological component of the S-l group was an independent factor affecting overall survival in multivariate analysis. CONCLUSION The long-term prognoses of the non-predominant poorly differentiated adenocarcinoma (PAC) groups were as poor as those of the predominant group. In particular, the histopathological component of the P-l and S-l groups could be classified into predominant PAC and SRCC subtypes for appropriate prognostic predictions.
Collapse
Affiliation(s)
- Heita Ozawa
- Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan.
| | - Shinichi Yamauchi
- Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan
| | - Hiroki Nakanishi
- Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan
| | - Junichi Sakamoto
- Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan
| | - Shin Fujita
- Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan
| | - Kenichi Sugihara
- Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan
| |
Collapse
|
21
|
Sakamoto J, Ozawa H, Nakanishi H, Fujita S. Oncologic outcomes after resection of para-aortic lymph node metastasis in left-sided colon and rectal cancer. PLoS One 2020; 15:e0241815. [PMID: 33196651 PMCID: PMC7668564 DOI: 10.1371/journal.pone.0241815] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Accepted: 10/20/2020] [Indexed: 11/30/2022] Open
Abstract
Aim The optimal surgical management strategy for para-aortic lymph node (PALN) metastasis has not attracted as much attention as surgery for liver or lung metastasis. The purpose of this retrospective study was to evaluate the oncologic outcomes after synchronous resection of PALN metastasis in left-sided colon and rectal cancer. Methods Between January 1986 and August 2016, 29 patients with pathologically positive PALN metastases who underwent curative resection at our hospital were retrospectively reviewed. We examined clinicopathological characteristics, long-term oncologic outcomes, and factors related to favorable prognosis in these patients. Results The 3-year overall survival and recurrence-free survival (RFS) rates were 50.5% and 17.2%, respectively. In total, 6 (20.7%) patients experienced no recurrence in the 3 years after surgery, while postoperative complications were seen in 9 (31.0%) patients. The 3-year RFS rate was significantly better in the pM1a group than in the pM1b/pM1c group (26.3% and 0.0%, respectively, p = 0.032). Conclusion PALN dissection for patients without other organ metastases in left-sided colon or rectal cancer is a good indication as it is for liver and lung metastasis.
Collapse
Affiliation(s)
- Junichi Sakamoto
- Department of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan
- * E-mail:
| | - Heita Ozawa
- Department of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan
| | - Hiroki Nakanishi
- Department of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan
| | - Shin Fujita
- Department of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan
| |
Collapse
|
22
|
Sho H, Fukui K, Yoneda S, Toyoda S, Ozawa H, Ishibashi C, Fujita Y, Eguchi H, Kozawa J, Shimomura I. Insulinoma induces a hyperinsulinemia-mediated decrease of GLUT2 and GLP1 receptor in normal pancreatic β-cells. Biochem Biophys Res Commun 2020; 534:702-706. [PMID: 33199025 DOI: 10.1016/j.bbrc.2020.11.014] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Accepted: 11/03/2020] [Indexed: 12/17/2022]
Abstract
There have been several clinical reports of transient postoperative hyperglycemia in patients with insulinoma, but the effect of insulinoma on normal β-cells has not been investigated. We examined the glucose transporter 2 (GLUT2) and glucagon-like peptide 1 receptor (GLP1R) expression in normal pancreatic β-cells of five patients with insulinoma and five patients with normal glucose tolerance (NGT) as controls. The positive rate of GLUT2-or GLP1R-positive islets in the nontumor area was calculated by the ratio with the analyzed islets. For functional in vitro analyses, q-PCR and Western blotting were performed after insulin loading on MIN6 cells. The expression rates of both GLUT2 and GLP1R were significantly lower in nontumor area islets of insulinoma patients than in patients with NGT (GLUT2: 31.6 ± 15.3% vs 95.9 ± 6.7%, p < 0.01, GLP1R: 66.8 ± 15.0% vs 96.7 ± 5.0%, p < 0.01). Exposure of MIN6 cells to high concentrations of insulin resulted in a significant decrease in GLUT2 protein for 12 h and GLP1R protein for 24 h (GLUT2; 1.00 ± 0.079 vs 0.81 ± 0.04. p = 0.02, GLP1R; 1.00 ± 0.10 vs 0.50 ± 0.24, p = 0.03) but not in those mRNAs. Our findings show that insulinoma is associated with the downregulation of GLUT2 and GLP1R expression in nontumor area islets. These phenomena may be caused by high levels of insulin.
Collapse
Affiliation(s)
- H Sho
- Departments of Metabolic Medicine, Graduate School of Medicine, Osaka University, Suita, Japan
| | - K Fukui
- Departments of Metabolic Medicine, Graduate School of Medicine, Osaka University, Suita, Japan.
| | - S Yoneda
- Departments of Metabolic Medicine, Graduate School of Medicine, Osaka University, Suita, Japan
| | - S Toyoda
- Departments of Metabolic Medicine, Graduate School of Medicine, Osaka University, Suita, Japan
| | - H Ozawa
- Departments of Metabolic Medicine, Graduate School of Medicine, Osaka University, Suita, Japan
| | - C Ishibashi
- Departments of Metabolic Medicine, Graduate School of Medicine, Osaka University, Suita, Japan
| | - Y Fujita
- Departments of Metabolic Medicine, Graduate School of Medicine, Osaka University, Suita, Japan; Departments of Community Medicine, Graduate School of Medicine, Osaka University, Suita, Japan
| | - H Eguchi
- Departments of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan
| | - J Kozawa
- Departments of Metabolic Medicine, Graduate School of Medicine, Osaka University, Suita, Japan; Departments of Diabetes Care Medicine, Graduate School of Medicine, Osaka University, Suita, Japan
| | - I Shimomura
- Departments of Metabolic Medicine, Graduate School of Medicine, Osaka University, Suita, Japan
| |
Collapse
|
23
|
Ozawa H, Nakanishi H, Sakamoto J, Suzuki Y, Fujita S. Prognostic impact of the number of lateral pelvic lymph node metastases on rectal cancer. Jpn J Clin Oncol 2020; 50:1254-1260. [PMID: 32687179 DOI: 10.1093/jjco/hyaa122] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2020] [Revised: 06/19/2020] [Accepted: 07/07/2020] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND This study aimed to clarify the number of lateral pelvic lymph node metastases of colorectal cancer for which prognosis could be improved by dissection. METHODS We analysed the data of 30 patients with lateral pelvic lymph node metastases of rectal cancer that underwent a total mesorectal excision with lateral pelvic lymph node dissection at our institute from 1986 to 2016. We performed survival analysis on the number of lateral pelvic lymph node metastases in each of these patients and identified an optimal cut-off point of the number of lateral pelvic lymph node metastases that would predict recurrence-free survival using the receiver operating characteristic curves and an Akaike information criterion value. RESULTS The 5-year recurrence-free survival and overall survival of patients with one or two lateral pelvic lymph node metastases were significantly better than that of those with three or more (5-year recurrence-free survival, 63.3 vs. 0.0%, respectively; hazard ratio, 0.23; 95% CI, 0.07-0.72; P = 0.0124) (5-year overall survival, 68.2 vs. 15.6%, respectively; hazard ratio, 0.29; 95% CI, 0.09-0.92; P = 0.0300). All of the metastatic lateral pelvic lymph nodes in the group with one or two lateral pelvic lymph node metastases were restricted to the internal iliac artery or obturator nerve regions. CONCLUSIONS The cut-off number of lateral pelvic lymph node metastases in the internal iliac artery or obturator nerve regions of colorectal cancer cases in whom prognosis was improved by lateral pelvic lymph node dissection was 2; patients who had <3 lateral pelvic lymph node metastases had better prognoses than those with ≥3 lateral pelvic lymph node metastases.
Collapse
Affiliation(s)
- Heita Ozawa
- Department of Surgery, Tochigi Cancer Center, Tochigi, Japan
| | | | | | | | - Shin Fujita
- Department of Surgery, Tochigi Cancer Center, Tochigi, Japan
| |
Collapse
|
24
|
Akagi T, Inomata M, Fujishima H, Fukuda M, Konishi T, Tsukamoto S, Teraishi F, Ozawa H, Tanaka K, Hida K, Sakai Y, Watanabe M. Preoperative chemoradiotherapy versus surgery alone for advanced low rectal cancer: a large multicenter cohort study in Japan. Surg Today 2020; 50:1507-1514. [PMID: 32524272 DOI: 10.1007/s00595-020-02034-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2020] [Accepted: 05/17/2020] [Indexed: 10/24/2022]
Abstract
PURPOSE To clarify the usefulness of chemoradiotherapy (CRT) for low rectal cancer, we investigated the current status of CRT in Japan and its short- and long-term outcomes versus surgery alone for low rectal cancer in a large multicenter cohort study. METHODS Between January 2010 and December 2011, data from 1608 patients with clinical Stage II-III rectal adenocarcinoma were collected from 69 specialized centers. Of these 1608 patients, 923 were diagnosed with clinical stage III low rectal cancer, 838 were enrolled in this study, divided into the surgery-alone group (n = 649) and preoperative CRT group (n = 189), and analyzed. RESULTS The following parameters were significantly lower in the CRT versus surgery-alone group: blood loss (210 vs. 431.5 mL), postoperative complications (27.5% vs 39.0%), and the incidence of anastomotic leakage (3.7% vs. 8.8%). The 3-year overall survival, relapse-free and local recurrence-free survival rates did not between the two groups to a statistically significant extent (91.2% vs. 87.4%, 68.8% vs. 66.4%, and 88.2% vs. 88.4%, respectively). CONCLUSIONS The present study revealed the current status of CRT for low rectal cancer in Japan. The results showed that CRT could be safely performed for advanced low rectal cancer in comparison to surgery alone.
Collapse
Affiliation(s)
- Tomonori Akagi
- Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu-City, Oita, 879-5593, Japan
| | - Masafumi Inomata
- Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu-City, Oita, 879-5593, Japan.
| | - Hajime Fujishima
- Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu-City, Oita, 879-5593, Japan
| | - Meiki Fukuda
- Department of Surgery, Kitano Hospital, Kyoto, Japan
| | - Tsuyoshi Konishi
- Department of Colorectal Surgery, Cancer Institute Center, Tokyo, Japan
| | | | | | - Heita Ozawa
- Department of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Japan
| | - Keitaro Tanaka
- Department of Colorectal Surgery, Osaka Medical College, Osaka, Japan
| | - Koya Hida
- Department of Surgery, Kyoto University, Kyoto, Japan
| | | | - Masahiko Watanabe
- Department of Surgery, Kitasato University Kitasato Institute Hospital, Tokyo, Japan
| |
Collapse
|
25
|
Fukui S, Ikeda Y, Kidoguchi G, Nakai T, Ozawa H, Kawaai S, Koido A, Ohara Y, Shimizu H, Tamaki H, Yamaguchi K, Okada M. FRI0535 NEWLY DETECTED HYPERTHYROIDISM WITH THERAPEUTIC INDICATIONS IN RHEUMATIC DISEASE PATIENTS AND HEALTHY CONTROLS IN JAPAN: A RETROSPECTIVE COHORT STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Thyroid disorders are known as common comorbidities of rheumatic diseases(RD) [1]. However, data regarding prevalence of hyperthyroidism with treatment indication in RD patients are limited.Objectives:This study aims to reveal and compare the frequency of newly developed hyperthyroidism with treatment indication between RD patients and healthy controls (HC), and identify risk factors to identify patients whose thyroid function should be followed up carefully.Methods:We retrospectively reviewed charts of RD patients and HC who had thyroid stimulating hormone (TSH) measured at least once between 2004 and 2018 from immuno-rheumatology center and preventive medicine center in St. Luke’s International Hospital, Japan. We compared frequency of hyperthyroidism requiring treatment (TSH ≦ 0.1μU/mL or for which physicians started treatment) with Kaplan-Meier curve and log rank test. Cox regression multivariate analysis was performed to reveal risk factors for the new onset of hyperthyroidism with treatment indication in participants without treatment-indicated hyperthyroidism at initial assessments.Results:Overall, 2307 RD patients and 78251 HC were included. Newly detected hyperthyroidism with treatment indication were significantly more frequent in RD patients at initial assessment (1.3% vs 0.5 %, p < 0.001) and in total (2.9% vs 1.7%, p<0.001) (Table 1, Figure 1). Cox regression multivariate analysis revealed systemic lupus erythematosis (SLE), polymyositis dermatomyositis (PMDM), mixed connective tissue disease (MCTD) as significant risk factors of new developments of hyperthyroidism during follow up after adjusting confounders. (Table 2)Table 1.Patients characteristics and results of hyperthyroidismRheumatic Disease (n = 2307)Control (n = 78251)p.valueAge(yr)53.7 (16.2)46.1 (11.9)<0.001Female (%)1826 (79.2)38632 (49.4)<0.001 Rheumatoid arthritis (%)1091 (47.3)-NA Spondyloarthritis161 (7.0)-NA ANA associated disease (%)944 (40.9)-NA SLE(%)363 (15.7)-NA SS (%)396 (17.2)-NA PMDM(%)104 (4.5)-NA SSc (%)222 (9.6)-NA MCTD (%)43 (1.9)-NA Vasculitis (%)202 (8.8)-NA Others (%)244 (10.6)-NATimes of TSH measurement2.0 [1.0, 5.0]5.0 [3.0, 9.0]<0.001Follow up of TSH (days)258.00 [0, 1315]1992 [958, 3632]<0.001Baseline TSH (μU/mL)2.28 (3.21)2.15 (4.07)0.137 ≦0.45 μU/mL (%)86 (3.7)1371 (1.8)<0.001 ≦0.1 μU/mL (%)29 (1.3)389 (0.5)<0.001Baseline FreeT4 (μU/mL)1.16 (0.24)1.30 (0.20)<0.001≧1.65 μU/mL (%)17 (0.8)2355 (3.0)<0.001TSH level in follow up ≦0.45 μU/mL (%)231 (0.0)3926 (5.0)<0.001 ≦0.1 μU/mL (%)84 (3.6)1388 (1.8)<0.001Newly detected hyperthyroidism with treatment indication (%)68 (2.9)1350 (1.7)<0.001 At initial assessment (%)29 (1.3)389 (0.5)<0.001 In follow up (%)39 (1.6)961 (1.2)<0.001Treatment for hyperthyroidism (%)21 (0.9)325 (0.4)0.002Figure 1.Hyperthyroidism with treatment indication in rheumatic patients and controlTable 2.Risk factors for newly detected hyperthyroidism with treatment indicationAdjusted HRp valueAge0.99 (0.98-0.99)< 0.001Female2.68 (2.31-3.12)< 0.001BMI1.04 (1.02-1.06)< 0.001Baseline TSH ≦ 0.455.71 (4.47-7.30)< 0.001Baseline Free T4 ≧ 1.651.16 (0.79-1.69)0.45Rheumatoid arthritis1.05 (0.50-2.21)0.90ANA associated diseases-- SLE2.29 (1.11-4.71)0.025 SS1.91 (0.91-4.01)0.089 PMDM12.90 (5.50-30.22)< 0.001 SSc0.67 (0.18-2.43)0.541 MCTD8.02 (2.62-24.51)< 0.001Vasculitis1.44 (0.35-5.92)0.610Spondyloarthritis3.04 (0.74-12.52)0.120Others1.98 (0.67-5.81)0.214Conclusion:Hyperthyroidism with therapeutic indications are considerably more frequent in RD patients (particularly with SLE, PMDM and MCTD) both at initial assessment and during follow up. We recommend routine screening at initial assessment and careful follow up of thyroid function test in those patients.References:[1] Rev Bras Rheumatol 2012;52(3):417-430Disclosure of Interests:None declared
Collapse
|
26
|
Tamaki H, Fukui S, Nakai T, Kidoguchi G, Kawaai S, Ozawa H, Ikeda Y, Koido A, Ohara Y, Shimizu H, Yamaguchi K, Okada M. AB0533 ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) IN GENERAL POPULATION WITHOUT ANCA ASSOCIATED VASCULITIS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.5075] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Currently it is hypothesized that many systemic autoimmune diseases occur due to environmental risk factors in addition to genetic risk factors. Anti-Neutrophil Cytoplasmic Antibody (ANCA) is mainly associated with three systemic autoimmune disease including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA). It is known that ANCA can be positive before clinical symptoms in patients with known diagnosis of GPA and ANCA titers rise before clinical manifestations appear. However, prevalence of ANCA among general population is not well known. It has not been described as well how many of people with positive ANCA eventually develop clinical manifestations of ANCA associated Vasculitis.Objectives:This study aims to estimate prevalence of ANCA in general population without ANCA associated Vasculitis. It also describes natural disease course of people with positive ANCA without ANCA associated Vasculitis. Risk factors for positive ANCA are also analyzed.Methods:This is a single center retrospective study at Center for Preventive Medicine of St. Luke’s International Hospital in Tokyo. ANCA was checked among the patients who wished to between 2018 and 2019. St. Luke’s Health Check-up Database (SLHCD) was utilized to collect the data. The patients whose serum was measured for ANCA were identified. The data for basic demographics, social habits, dietary habits and laboratory data were extracted. The charts of the patients with positive ANCA were reviewed.Results:Sera of total 1204 people were checked for ANCA. Of these 1204 people, 587 (48.8%) are male and the mean age was 55.8 years (32.6 to 79). There were total 11 patients with positive ANCA. Myeloperoxidase ANCA (MPO-ANCA) was positive for 3 patients and proteinase 3 ANCA (PR3-ANCA) was positive for 8 patients. Of these 11 patients, 5 were male (45.5%) and the mean age was 54.6 years. Two patients had history of autoimmune disease (primary biliary cirrhosis and ulcerative colitis). Five patients were evaluated by rheumatologists with the median follow-up period of 274 days. None of them developed clinical signs and symptoms of ANCA associated Vasculitis. Four out of five patients had ANCA checked later, two of which turned negative. The prevalence of ANCA in this cohort was 0.9% (95% confidence interval [95% CI]: 0.5% to 1.6%). Univariate analysis was performed to identify risk factors of positive ANCA. The variables analyzed include age, gender, body mass index (BMI), smoking habits, alcohol intake, dietary habits (fruits, fish, red meat), hypertension, dyslipidemia, and laboratory data. None of these variables demonstrated statistically significant differences except for positive rheumatoid factor (ANCA positive group: 33 % vs ANCA negative group: 9.1%, p value = 0.044).Conclusion:The prevalence of ANCA in this cohort was 0.9% (95% CI: 0.5% to 1.6%). None of them who had a follow-up developed ANCA associated Vasculitis during the follow-up period. Longer follow-up and more patients are necessary to determine natural course of people with positive ANCA.Disclosure of Interests:None declared
Collapse
|
27
|
Kawaai S, Fukui S, Nakai T, Kidoguchi G, Ozawa H, Ikeda Y, Koido A, Ohara Y, Shimizu H, Tamaki H, Yamaguchi K, Okada M. SAT0525 EFFICACY AND SAFETY OF MZR FOR IgG4-RELATED DISEASE. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1983] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:IgG4-Related Disease (IgG4RD) is known to cause multiple organ lesions with infiltration of IgG4-positive plasma cells, and patients often have relapses with tapering treatments despite an initial good response to glucocorticoids therapy. Mizoribine (MZR) is an immunosuppressant working as an inhibitor of purine synthesis, which mechanism of action is similar to mycophenolate mofetil. Data regarding the efficacy and safety of MZR on IgG4RD is limited although some previous case reports1showed effectiveness for IgG4RD.Objectives:This study aims to assess the efficacy and safety of MZR in patients with IgG4RD.Methods:We retrospectively reviewed charts of IgG4RD patients who used MZR between January 2004 and December 2019 at Immuno-Rheumatology Center in St. Luke’s International Hospital, Tokyo, Japan. We investigated basic demographics, involved organs, results of blood tests including IgG and IgG4 titer, and medications used including glucocorticoid and other immunosuppressants (IS). We followed IgG4 titer, dose of glucocorticoid, flare of disease and retention of MZR at the beginning, 6 and 12months after starting MZR. We compared changes in PSL (prednisolone) doses and IgG4 titers over time using Friedman test with Bonferroni correction. We also checked adverse events during follow up.Results:Twenty-two patients with IgG4RD who used MZR were included. Median age was 62 years old, and 15 (68.2%) patients are male. Lacrimal and salivary glands, pancreatitis and retroperitoneal fibrosis were common lesions. All patients were initially treated with glucocorticoids. Flare was observed in 5 (22.7 %) patients before initiation of MZR. The number of patients who continued MZR without flare are 19 (86.4 %) at 6 months, and 14 (73.7 %) at 12 months. IgG4 titer significantly declined at 6 and 12 months from baseline although significant consecutive decrease in PSL dose (Figure 1, 2). Liver dysfunctions are commonest adverse events (n=16, 72.7%) but mild (grade1; n=15, 68.2%) and most cases are apparently due to other reasons. Serious infection (SI) occurred in 3 (13.6%) patients in total follow up, however no SI were observed during 1 year after MZR treatment.Conclusion:MZR can be safely used in patients of IgG4RD with high retention rate, and seemed to have steroid-sparing effect. Prospective comparative studies are needed.References:[1]Nanke Y, Kobashigawa T, Yago T, Kamatani N, Kotake S. A case of Mikulicz’s disease, IgG4-related plasmacytic syndrome, successfully treated by corticosteroid and mizoribine, and then by mizoribine alone. Intern Med 49: 1449-1453, 2010.Table 1.Patient characteristics Table 2.Disease and treatment status before and after initiation of MZR Figure 1.Serum IgG4 level changesFigure 2.Changes in the PSL dose over timeDisclosure of Interests:None declared
Collapse
|
28
|
Kidoguchi G, Fukui S, Nakai T, Kawaai S, Ozawa H, Ikeda Y, Koido A, Ohara Y, Shimizu H, Yamaguchi K, Tamaki H, Okada M. AB0198 SMOKING AND POSITIVITY OF RHEUMATOID FACTOR AND ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY IN THE GENERAL POPULATION. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:It is well known that rheumatoid arthritis (RA) occurs due to environmental risk factors in addition to genetic risk factors. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACPA) are strongly associated with RA, and these biomarkers could turn to be positive before development of clinical symptoms. While smoking, particularly Brinkman index (BI) is well known as a risk factor for RA and ACPA positivity, it is still unclear whether smoking intensity or smoking duration contribute more to positive RF and ACPA.Objectives:This study aims to evaluate risk factors for RF and ACPA positivity in the general population. It also describes whether smoking intensity, duration, and BI are significant.Methods:This is a cross-sectional, observational, single center study. We reviewed the baseline characteristics of the general population who checked RF and ACPA at Preventive Medicine Center in St. Luke’s International Hospital, Tokyo, Japan from January 2004 to December 2018.The data for basic demographics, dietary habit, smoking intensity, smoking duration, BI, and blood tests including RF and ACPA were extracted. The data was analyzed statistically.Results:A total of 127472 people who checked RF are included. Of these 127472 people, 64504 (50.6%) are male and the mean age was 44.9 years. RF was positive in 11477 people (9.0%). Among these, 1667 (1.2%) were checked for ACPA, and 21 people (1.3%) had positive ACPA. None of variables demonstrated significant association with RF positivity. In contrast, BI and smoking duration was significantly associated with an increased risk of ACPA positivity (13.3 years vs 7.49 years, p value = 0.023), although the number of cigarettes smoked was not. The smoking duration for 10 years or more was associated with an increased risk of ACPA positivity even after adjusted for age and sex (adjusted hazard ratio: 2.47 [95% confidence interval: 1.04-5.87]; p=0.04).Conclusion:In this study, no significant risk factor for positive RF was found. Even smoking was not associated with RF positivity. On the other hand, smoking duration, not smoking intensity was significantly associated with an increased risk of ACPA positivity.References:[1]Verpoort KN. Association of smoking with the constitution of the anti-cyclic citrullinated peptide response in the absence of HLA-DRB1 shared epitope alleles. Arthritis Rheum 2007;56:29138.Table 1.Patient characteristics with RF and ACPA positivityRF positive (n=11477)RF negative (n=115995)p valueACPA positive (n=21)ACPA negative (n=1646)p valueAge44.86 (12.32)44.94 (12.47)0.5437.90 (9.07)45.26 (12.58)0.008Male (%)5659 (49.3)57309 (49.4)0.84511 (52.4)834 (50.7)1Body Mass Index22.33 (3.38)22.35 (3.40)0.52121.64 (3.28)22.34 (3.37)0.346Smoker, total (%)4509 (39.3)45738 (39.4)0.77212 (57.1)642 (39.0)0.115Current smoker (%)1959 (17.1)20483 (17.7)0.1148 (38.1)277 (16.8)0.017Previous smoker (%)2550 (22.2)25255 (21.8)0.2714 (19.0)365 (22.2)1Brinkman index144.8 (299.3)145.2 (313.8)0.897280.9 (409.7)145.3 (300.3)0.041Number of cigarettes (/day)17.7 (18.5)17.4 (13.3)0.16619.8 (12.0)17.4 (12.1)0.511Smoking Duration (years)7.43 (11.68)7.45 (11.66)0.85113.33 (14.11)7.49 (11.68)0.023Alcohol Drinker (%)6972 (60.7)70010 (60.4)0.41810 (47.6)1005 (61.1)0.261Alcohol Intake (g/day)13.67 (21.88)13.58 (21.32)0.67616.70 (26.89)14.06 (22.16)0.59Exercise ≧3 times/week (%)2792 (24.3)28293 (24.4)0.8825 (23.8)402 (24.4)1White blood cell (103/μL)5.32 (1.46)5.35 (1.50)0.135.59 (2.05)5.37 (1.54)0.52Hemoglobin (g/dL)13.82 (1.44)13.82 (1.45)0.75314.12 (1.03)13.83 (1.43)0.36Creatinine (mg/dL)0.73 (0.20)0.73 (0.25)0.1940.76 (0.16)0.73 (0.18)0.586AST (U/L)21.89 (9.39)21.93 (11.65)0.78220.95 (6.02)21.68 (8.29)0.69LDL cholesterol (mg/dL)115.41 (30.90)115.48 (30.77)0.815112.62 (33.26)115.36 (31.03)0.688Triglyceride (mg/dL)97.63 (78.46)97.70 (80.36)0.929100.57 (63.40)97.85 (78.37)0.874Uric Acid (mg/dL)5.32 (1.42)5.33 (1.42)0.6235.76 (1.34)5.34 (1.42)0.172Disclosure of Interests:None declared
Collapse
|
29
|
Ozawa H, Kotake K, Ike H, Sugihara K. Prognostic Impact of the Length of the Distal Resection Margin in Rectosigmoid Cancer: An Analysis of the JSCCR Database between 1995 and 2004. J Anus Rectum Colon 2020; 4:59-66. [PMID: 32346644 PMCID: PMC7186012 DOI: 10.23922/jarc.2019-013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/11/2019] [Accepted: 01/16/2020] [Indexed: 11/30/2022]
Abstract
Objectives The necessary and sufficient length of the distal resection margin (l-DRM) for rectosigmoid cancer remains controversial. This study evaluated the validity of the 3-cm l-DRM rule for rectosigmoid cancer in the Japanese classification of colorectal cancer. Methods We retrospectively reviewed 1,443 patients with cT3 and cT4 rectosigmoid cancer who underwent R0 resection in Japanese institutions between 1995 and 2004. We identified the optimal cutoff point of the l-DRM affecting overall survival (OS) rate using a multivariate Cox regression analysis model. Using this cutoff point, the patients were divided into two groups after balancing the potential confounding factors of the l-DRM using propensity score matching, and the OS rates of the two groups were compared. Results A multivariate Cox regression analysis model revealed that the l-DRM of 4 cm was the best cutoff point with the greatest impact on OS rate (hazard ratio [HR], 1.37; 95% confidence interval [CI], 1.00-1.84; P = 0.0452) and with the lowest Akaike information criterion value. In the matched cohort study, the OS rate of patients who had l-DRM of 4 cm or more was significantly higher than that of patients who had l-DRM < 4 cm (n = 402; 5-year OS rates, 87.6% vs. 80.3%, respectively; HR, 1.60; 95% CI, 1.09-2.31; P = 0.0136). Conclusions For cT3 and cT4 rectosigmoid cancer, l-DRM of 4 cm may be an appropriate landmark for a curative intent surgery, and we were unable to definitively confirm the validity of the Japanese 3-cm l-DRM rule.
Collapse
Affiliation(s)
- Heita Ozawa
- Department of Surgery, Tochigi Cancer Center, Utsunomiya, Japan
| | - Kenjiro Kotake
- Department of Gastroenterological Surgery, Sano City Hospital, Sano, Japan
| | - Hideyuki Ike
- Department of Surgery, Yokohama Hodogaya Central Hospital, Yokohama, Japan
| | | |
Collapse
|
30
|
Tanaka T, Ozawa H, Nakagawa Y, Hirata A, Fujita S, Sugihara K. Verifying the M1c category of CRC: analysis of the data from a Japanese multi-institutional database. Int J Colorectal Dis 2020; 35:125-131. [PMID: 31797096 DOI: 10.1007/s00384-019-03408-w] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 09/16/2019] [Indexed: 02/04/2023]
Abstract
BACKGROUND/AIMS In the TNM classification 8th edition, colorectal cancer (CRC) with peritoneal metastasis, one of the most poor prognostic factors, is classified as M1c (stage IVC), regardless of the presence/absence of other distant metastasis. Several cases with peritoneal metastasis have been successfully managed by surgical treatment; therefore, there is need to give more consideration for uniform differentiation of peritoneal metastasis. This study was aimed at verifying the classification of M1c in CRC. MATERIALS AND METHODS Data from a multi-institutional retrospective cohort of 2929 CRC patients who were diagnosed as having stage IV CRC from 1997 to 2007 were analyzed. Peritoneal metastasis alone was defined as M1c1 and peritoneal metastasis with other organ metastasis was defined as M1c2. RESULTS The 3-year OS of patients with M1c1 was significantly higher than that of patients with M1b (25.6% vs. 18.1%; HR 0.77; 95% confidence interval (CI) 0.65-0.92; p = 0.005); in particular, the prognosis of patients with M1c1 with localized peritoneal metastasis and R0 resection was equivalent to that of patients with M1a (3-year OS 40.5% vs. 39.2%, p = 0.41). On the other hand, among the stage IV cases, patients with M1c2 had a low R0 resection rate (5.9%) and the worst prognosis (3-year OS, 9.1%). CONCLUSIONS The prognosis of M1c1 with localized peritoneal metastasis is relatively good, and can be further improved by surgical intervention. Combined evaluation of the M1c1/2 classification with the peritoneal metastasis grade may help in establishing more individualized treatment strategies.
Collapse
Affiliation(s)
- Toshimichi Tanaka
- Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan
| | - Heita Ozawa
- Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan.
| | - Yusuke Nakagawa
- Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan
| | - Akira Hirata
- Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan
| | - Shin Fujita
- Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan
| | - Kenichi Sugihara
- Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan
| |
Collapse
|
31
|
Ozawa H, Hoashi T, Nakata T, Shimada M, Ichikawa H. P37 Long-term outcomes of patients at risks for Fontan operation: role of temporary fenestration. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehz872.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Purpose
Whereas fenestration at Fontan operation was reported to be effective for smooth initiation to Fontan circulation, subsequently developed aortopulmonary collateral arteries under the presence of remaining hypoxia were a matter of concern.So as our institutional policy, it is closed as much and early as possible (temporary fenestration). This study aimed to reveal long-term outcomes for patients at riskswho underwent Fontan operation with temporary fenestration.
Methods
Of 107 patients undergoing Fontan operation from 1995 to 2004, 79 patients (73.8%) were free from any risks (NR group) and 28 patients (26.2%) had risks for Fontan operation (R group). Hypoplastic left heart syndrome, heterotaxy syndrome with obstructive total anomalous of pulmonary venous connection, and individual cases with high preoperative pulmonary artery pressure (PAP), systemic ventricular end diastolic pressure (SVEDP) or low ejection fraction (SVEF) were defined as a risk for Fontan completion.Age at Fontan operation was older in R group (6.6 vs 2.3years-old, p = 0.0004). Preoperative PAP (12.8 vs 11.3mmHg, p = 0.03) and SVEDP (8.8 vs 7.1mmHg, p = 0.02) were higher and SVEF (53.7 vs 60.0%, p = 0.002) was lower in R group. Pulmonary vascular resistance (PVR) was not different. Fenestration was created in all patients in R group, then it was closed at the mean duration of 2.9 years after Fontan operation.
Results
Freedom from death or protein-losing enteropathy rate at 5, 10, and 15 years after Fontan operation were 97, 96, and 93% in NR group and 96, 93, and 86% in R group (log-rank: p = 0.20). Fifty-one patients (64.6%) in NR group and 17 patients (60.7%) in R group underwent serial catheter examinations at 5, 10, and 15 years after Fontan operation and exercise capacity testing at 15 years after Fontan operation (Figure). In R group, arterial oxygen saturation was lower and PVR was higher even after close of fenestration (Figure). In addition, 12 patients (71%) in R group developed significant veno-venous collaterals, which were defined by more than 3mm in diameter of collateral veins or a condition where pulmonary veins were contrasted in venography. On the contrary, cardiac index (CI), SVEDP, and PAP were not different and no significant difference on peak oxygen uptake and anaerobic threshold were observed between in 2 groups.
Conclusions
Although the mild cyanosis remained due to the development of veno-venous collaterals after the closure of temporary fenestration, CI, SVEDP and PAP well maintained in patients at risk for Fontan operation. These results might to lead acceptable life prognosis and freedom fromprotein-losing enteropathy rate for patients at risk for Fontan operation.
Abstract P37 Figure
Collapse
Affiliation(s)
- H Ozawa
- National Cerebral & Cardiovascular Center, Suita, Japan
| | - T Hoashi
- National Cerebral & Cardiovascular Center, Suita, Japan
| | - T Nakata
- National Cerebral & Cardiovascular Center, Suita, Japan
| | - M Shimada
- National Cerebral & Cardiovascular Center, Suita, Japan
| | - H Ichikawa
- National Cerebral & Cardiovascular Center, Suita, Japan
| |
Collapse
|
32
|
Itabashi M, Yamamoto H, Tomita N, Inomata M, Murata K, Hayashi S, Miyake Y, Igarashi S, Kato T, Noura S, Furuhata T, Ozawa H, Takemasa I, Yasui M, Takeyama H, Okamura S, Ohno Y, Matsuura N. Lymph Node Positivity in One-Step Nucleic Acid Amplification is a Prognostic Factor for Postoperative Cancer Recurrence in Patients with Stage II Colorectal Cancer: A Prospective, Multicenter Study. Ann Surg Oncol 2019; 27:1077-1083. [PMID: 31722072 PMCID: PMC7060165 DOI: 10.1245/s10434-019-07971-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Indexed: 01/11/2023]
Abstract
Background For colorectal cancer (CRC) patients, the standard histological lymph node (LN) evaluation has low sensitivity. Our previously developed one-step nucleic acid amplification (OSNA™) assay measures cytokeratin 19 gene expression in whole LNs. We recently showed that 17.6% of pN0 stage II CRC patients were OSNA positive, suggesting a correlation between OSNA results and disease recurrence. This multicenter, prospective study investigateed the prognostic value of the OSNA assay for pStage II CRC patients. Methods We examined 204 CRC patients who were preoperatively diagnosed as cN0 and cN1 and surgically treated at 11 medical institutions across Japan. Nine patients were excluded, and 195 patients (Stage I: n = 50, Stage II: n = 70, Stage III: n = 75) were examined. All LNs, harvested from patients, were examined histopathologically using one-slice hematoxylin–eosin staining. Furthermore, half of the LNs was examined by the OSNA assay. Patients were classified according to the UICC staging criteria and OSNA results, and the 3-year, disease-free survival (DFS) of each cohort was analyzed. Results Average 21.2 LNs/patient were subject to pathological examination. Approximately half of all harvested LNs (average, 9.4 LNs/patient) were suitable for the OSNA assay. Significantly lower 3-year DFS rates were observed in pStage (pathological Stage) II OSNA-positive patients than in OSNA-negative patients (p = 0.005). Among all assessed clinical and pathological parameters, only the OSNA result significantly affected 3-year DFS rates in pStage II CRC patients (p = 0.027). Conclusions This study shows that OSNA positivity is a risk factor for recurrence of the patients with pStage II CRC. Electronic supplementary material The online version of this article (10.1245/s10434-019-07971-y) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Michio Itabashi
- Institute of Gastroenterology, Tokyo Women's Medical University, Shinjuku, Japan
| | - Hirofumi Yamamoto
- Department of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, Osaka University, Suita, Japan.
| | - Naohiro Tomita
- Division of Lower GI Surgery, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan
| | - Masafumi Inomata
- Department of Gastroenterological and Pediatric Surgery, Faculty of Medicine, Oita University, Oita, Japan
| | - Kohei Murata
- Department of Surgery, Kansai Rosai Hospital, Amagasaki, Japan
| | - Shigeoki Hayashi
- Department of Digestive Surgery, Nihon University Hospital, Chiyoda, Japan
| | - Yasuhiro Miyake
- Department of Surgery, Osaka Minato Central Hospital, Osaka, Japan
| | - Seiji Igarashi
- Division of Pathology, Tsuboi Cancer Center Hospital, Koriyama, Japan
| | - Takeshi Kato
- Department of Colorectal Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan
| | - Shingo Noura
- Department of Surgery, Osaka Rosai Hospital, Sakai, Japan
| | - Tomohisa Furuhata
- Division of Gastroenterological and General Surgery, St. Marianna University Toyoko Hospital, Kawasaki, Japan
| | - Heita Ozawa
- Department of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Japan
| | - Ichiro Takemasa
- Department of Surgery, Surgical Oncology and Science, Sapporo Medical University, Sapporo, Japan
| | - Masayoshi Yasui
- Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan
| | | | - Shu Okamura
- Department of Surgery, Suita Municipal Hospital, Suita, Japan
| | - Yuko Ohno
- Department of Mathematical Health Science, Graduate School of Medicine, Osaka University, Suita, Japan
| | | |
Collapse
|
33
|
Ishikawa T, Oki E, Shinto E, Shimokawa M, Yamaguchi S, Ishiguro M, Hasegawa S, Takii Y, Ishida H, Kusumoto T, Morita M, Tomita N, Shiozawa M, Tanaka M, Ozawa H, Hashiguchi Y, Ohnuma S, Tada S, Matsushima T, Hase K. The 55 STAR study: Prognostic and predictive value of the 55-gene classifier (55GC) in stage III colon cancer. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.3597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3597 Background: Patient prognosis can be predicted based on cancer subtypes classified according to DNA microarray results. The most robust classification system involves the consensus molecular subtypes, which uses over 600 genes for classification. To simplify this classification, we recently constructed a 55-gene classifier (55GC) to classify colon cancer (CC) into three subtypes with different recurrence rates: “microsatellite instability (MSI)-like,” “chromosomal instability (CIN)-like,” and “stromal” colon cancers. The 55GC has been reported to be a useful and reproducible grading system for stage II CC recurrence risk stratification. This study aimed to explore the usefulness of 55GC for classifying stage III CC patients. Methods: We retrospectively identified stage III CC patients aged 20-79 years who underwent curative surgery and received adjuvant chemotherapy with or without oxaliplatin (OX) between 2009 and 2012 from 15 institutions. Propensity score matching was used to adjust for the number of lymph node metastases, tumor location, sex, and age. Results: Among 938 eligible patients, 203 and 201 cases involving adjuvant chemotherapy with and without OX were selected, respectively, using propensity score matching. Ninety-five cases each from groups were analyzed after exclusion of cases involving low-quality specimens and those involving chemotherapy for < 3 months. The 5-year relapse-free survival (RFS) in patients receiving adjuvant chemotherapy with and without OX were 77.1% and 73.7%, respectively. Classification of the stage III CC according to 55GC and related 5-year RFS rates were as follows: stromal (N = 60), 66.6%; CIN-like (N = 78), 80.5%; and MSI-like (N = 52), 78.4%. The HRs for 5-year RFS for adjuvant chemotherapy with and without OX in each subtype were as follows: stromal, HR = 0.791 (95% CI = 0.329-1.901); CIN-like, HR = 1.241 (95% CI = 0.465-3.308); and MSI-like, HR = 0.495 (95% CI = 0.145-1.692). Conclusions: The stromal subtype showed poor prognosis in stage III as well as stage II patients. Oxaliplatin had a good additive effect in adjuvant chemotherapy for MSI-like subtype. The 55GC is useful for predicting the efficacy of adjuvant chemotherapy for CC.
Collapse
Affiliation(s)
| | - Eiji Oki
- Kyushu University, Fukuoka, Japan
| | - Eiji Shinto
- National Defense Medical College, Tokorozawa, Japan
| | | | - Shigeki Yamaguchi
- Saitama Medical University International Medical Center, Hidaka, Japan
| | | | | | | | - Hideyuki Ishida
- Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
| | | | | | | | | | | | | | | | | | | | | | - Kazuo Hase
- National Defense Medical College, Tokorozawa, Japan
| |
Collapse
|
34
|
Masuyama Y, Mizuno K, Ozawa H, Ishiwata H, Hatano Y, Ohshima T, Iwasaki T, Hatano M. Extending coherence time of macro-scale diamond magnetometer by dynamical decoupling with coplanar waveguide resonator. Rev Sci Instrum 2018; 89:125007. [PMID: 30599584 DOI: 10.1063/1.5047078] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Accepted: 11/15/2018] [Indexed: 06/09/2023]
Abstract
Ultimate sensitivity for quantum magnetometry using nitrogen-vacancy (NV) centers in a diamond is limited by a number of NV centers and coherence time. Microwave irradiation with a high and homogeneous power density for a large detection volume is necessary to achieve a highly sensitive magnetometer. Here, we demonstrate a microwave resonator to enhance the power density of the microwave field and an optical system with a detection volume of 1.4 × 10-3 mm3. The strong microwave field enables us to achieve 48 ns Rabi oscillation which is sufficiently faster than the phase relaxation time of NV centers. This system combined with a decoupling pulse sequence, XY16, extends the spin coherence time (T 2) up to 27 times longer than that with a spin echo method. Consequently, we obtained an AC magnetic field sensitivity of 10.8 pt/ Hz using the dynamical decoupling pulse sequence.
Collapse
Affiliation(s)
- Y Masuyama
- Department of Physical Electronics, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8552, Japan
| | - K Mizuno
- Department of Physical Electronics, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8552, Japan
| | - H Ozawa
- Department of Physical Electronics, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8552, Japan
| | - H Ishiwata
- Department of Physical Electronics, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8552, Japan
| | - Y Hatano
- Institute for Protein Research, Osaka University, Yamadaoka, Suita, Osaka 5650871, Japan
| | - T Ohshima
- Takasaki Advanced Radiation Research Institute, National Institutes for Quantum and Radiological Science and Technology, Takasaki, Gunma 370-1292, Japan
| | - T Iwasaki
- Department of Physical Electronics, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8552, Japan
| | - M Hatano
- Department of Physical Electronics, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8552, Japan
| |
Collapse
|
35
|
Matsuura N, Tomita N, Inomata M, Murata K, Hayashi S, Miyake Y, Igarashi S, Itabashi M, Kato T, Noura S, Furuhata T, Ozawa H, Takemasa I, Yasui M, Takeyama H, Okamura O, Yamamoto H. Clinical impact of molecular positive lymph node status in colorectal cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Okamura R, Hida K, Yamaguchi T, Akagi T, Konishi T, Yamamoto M, Ota M, Matoba S, Bando H, Goto S, Sakai Y, Watanabe M, Watanabe K, Otsuka K, Takemasa I, Tanaka K, Ikeda M, Matsuda C, Fukuda M, Hasegawa J, Akamoto S, Shiozawa M, Tsuruta A, Akiyoshi T, Kato T, Tsukamoto S, Ito M, Naito M, Kanazawa A, Takahashi T, Ueki T, Hayashi Y, Morita S, Yamaguchi T, Nakanishi M, Hasegawa H, Okamoto K, Teraishi F, Sumi Y, Tashiro J, Yatsuoka T, Nishimura Y, Okita K, Kobatake T, Horie H, Miyakura Y, Ro H, Nagakari K, Hidaka E, Umemoto T, Nishigori H, Murata K, Wakayama F, Makizumi R, Fujii S, Sunami E, Kobayashi H, Nakagawa R, Enomoto T, Ohnuma S, Higashijima J, Ozawa H, Ashida K, Fujita F, Uehara K, Maruyama S, Ohyama M, Yamamoto S, Hinoi T, Yoshimitsu M, Okajima M, Tanimura S, Kawasaki M, Ide Y, Hazama S, Watanabe J, Inagaki D, Toyokawa A. Local control of sphincter-preserving procedures and abdominoperineal resection for locally advanced low rectal cancer: Propensity score matched analysis. Ann Gastroenterol Surg 2017; 1:199-207. [PMID: 29863157 PMCID: PMC5881346 DOI: 10.1002/ags3.12032] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/15/2017] [Accepted: 07/10/2017] [Indexed: 12/13/2022] Open
Abstract
Sphincter‐preserving procedures (SPPs) for surgical treatment of low‐lying rectal tumors have advanced considerably. However, their oncological safety for locally advanced low rectal cancer compared with abdominoperineal resection (APR) is contentious. We retrospectively analyzed cohort data of 1500 consecutive patients who underwent elective resection for stage II‐III rectal cancer between 2010 and 2011. Patients with tumors 2‐5 cm from the anal verge and clinical stage T3‐4 were eligible. Primary outcome was 3‐year local recurrence rate, and confounding effects were minimized by propensity score matching. The study involved 794 patients (456 SPPs and 338 APR). Before matching, candidates for APR were more likely to have lower and advanced lesions, whereas SPPs were carried out more often following preoperative treatment, by laparoscopic approach, and at institutions with higher case volume. After matching, 398 patients (199 each for SPPs and APR) were included in the analysis sample. Postoperative morbidity was similar between the SPPs and APR groups (38% vs 39%; RR 0.98, 95% CI 0.77‐1.27). Margin involvement was present in eight patients in the SPPs group (one and seven at the distal and radial margins, respectively) and in 12 patients in the APR group. No difference in 3‐year local recurrence rate was noted between the two groups (11% vs 14%; HR 0.77, 95% CI 0.42‐1.41). In this observational study, comparability was ensured by adjusting for possible confounding factors. Our results suggest that SPPs and APR for locally advanced low rectal cancer have demonstrably equivalent oncological local control.
Collapse
Affiliation(s)
| | - Koya Hida
- Department of Surgery Kyoto University Kyoto Japan
| | - Tomohiro Yamaguchi
- Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan
| | - Tomonori Akagi
- Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan
| | - Tsuyoshi Konishi
- Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan
| | - Michio Yamamoto
- Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan
| | - Mitsuyoshi Ota
- Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan
| | - Shuichiro Matoba
- Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan
| | - Hiroyuki Bando
- Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan
| | - Saori Goto
- Department of Surgery Kyoto University Kyoto Japan
| | | | - Masahiko Watanabe
- Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | | | - Kazuteru Watanabe
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Koki Otsuka
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Ichiro Takemasa
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Keitaro Tanaka
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Masataka Ikeda
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Chu Matsuda
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Meiki Fukuda
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Junichi Hasegawa
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Shintaro Akamoto
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Manabu Shiozawa
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Atsushi Tsuruta
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Takashi Akiyoshi
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Takeshi Kato
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Shunsuke Tsukamoto
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Masaaki Ito
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Masaki Naito
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Akiyoshi Kanazawa
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Takao Takahashi
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Takashi Ueki
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Yuri Hayashi
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Satoshi Morita
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Takashi Yamaguchi
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Masayoshi Nakanishi
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Hirotoshi Hasegawa
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Ken Okamoto
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Fuminori Teraishi
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Yasuo Sumi
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Jo Tashiro
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Toshimasa Yatsuoka
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Yoji Nishimura
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Kenji Okita
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Takaya Kobatake
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Hisanaga Horie
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Yasuyuki Miyakura
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Hisashi Ro
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Kunihiko Nagakari
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Eiji Hidaka
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Takehiro Umemoto
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Hideaki Nishigori
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Kohei Murata
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Fuminori Wakayama
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Ryoji Makizumi
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Shoichi Fujii
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Eiji Sunami
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Hirotoshi Kobayashi
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Ryosuke Nakagawa
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Toshiyuki Enomoto
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Shinobu Ohnuma
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Jun Higashijima
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Heita Ozawa
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Keigo Ashida
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Fumihiko Fujita
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Keisuke Uehara
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Satoshi Maruyama
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Masato Ohyama
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Seiichiro Yamamoto
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Takao Hinoi
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Masanori Yoshimitsu
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Masazumi Okajima
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Shu Tanimura
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Masayasu Kawasaki
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Yoshihito Ide
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Shoichi Hazama
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Jun Watanabe
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Daisuke Inagaki
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| | - Akihiro Toyokawa
- Department of Surgery Kyoto University Kyoto Japan.,Division of Colon and Rectal Surgery Shizuoka Cancer Center Hospital Shizuoka Japan.,Department of Gastroenterological and Pediatric Surgery Oita University Faculty of Medicine Oita Japan.,Department of Gastroenterological Surgery Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan.,Department of Data Science Institute for Advancement of Clinical and Translational Science Kyoto University Hospital Kyoto Japan.,Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan.,Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan.,Department of Gastroenterological Surgery Ishikawa Prefectural Central Hospital Ishikawa Japan.,Department of Surgery Kitasato University School of Medicine Kanagawa Japan
| |
Collapse
|
37
|
Imai T, Ichimura M, Nakashima Y, Katanuma I, Yoshikawa M, Kariya T, Minami R, Miyata Y, Yamaguchi Y, Ikezoe R, Shimozuma T, Kubo S, Yoshimura Y, Takahashi H, Mutoh T, Sakamoto K, Mizuguchi M, Ota M, Ozawa H, Hosoi K, Yaguchi F, Yonenaga R, Imai Y, Murakani T, Yagi K, Nakamura T, Aoki1 H, Iizumi H, Ishii T, Kondou H, Takeda H, Ichioka N, Masaki S, Yokoyama T. Status and Plan of GAMMA 10 Tandem Mirror Program. Fusion Science and Technology 2017. [DOI: 10.13182/fst11-a11563] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Imai
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - M. Ichimura
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - Y. Nakashima
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - I. Katanuma
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - M. Yoshikawa
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Kariya
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - R. Minami
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - Y. Miyata
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - Y. Yamaguchi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - R. Ikezoe
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Shimozuma
- National Institute of Fusion Science(NIFS), Toki, Japan
| | - S. Kubo
- National Institute of Fusion Science(NIFS), Toki, Japan
| | - Y. Yoshimura
- National Institute of Fusion Science(NIFS), Toki, Japan
| | - H. Takahashi
- National Institute of Fusion Science(NIFS), Toki, Japan
| | - T. Mutoh
- National Institute of Fusion Science(NIFS), Toki, Japan
| | - K. Sakamoto
- Japan Atomic Energy Research Institute(JAEA), Naka, Japan
| | - M. Mizuguchi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - M. Ota
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - H. Ozawa
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - K. Hosoi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - F. Yaguchi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - R. Yonenaga
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - Y. Imai
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Murakani
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - K. Yagi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | | | - H. Aoki1
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - H. Iizumi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Ishii
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - H. Kondou
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - H. Takeda
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - N. Ichioka
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - S. Masaki
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Yokoyama
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | | |
Collapse
|
38
|
Nakashima Y, Takeda H, Yonenaga R, Hosoi K, Ozawa H, Ishii T, Nishino N, Ichimura M, Kariya T, Katanuma I, Minami R, Miyata Y, Yamaguchi Y, Yoshikawa M, Imai T. Research Plan for Divertor Simulation Studies and Its Recent Results Using the GAMMA 10 Tandem Mirror. Fusion Science and Technology 2017. [DOI: 10.13182/fst11-a11575] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Y. Nakashima
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - H. Takeda
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - R. Yonenaga
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - K. Hosoi
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - H. Ozawa
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - T. Ishii
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - N. Nishino
- Graduate School of Engineering, Hiroshima University, Higashi-Hiroshima, 739-8527, Japan
| | - M. Ichimura
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - T. Kariya
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - I. Katanuma
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - R. Minami
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - Y. Miyata
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - Y. Yamaguchi
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - M. Yoshikawa
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - T. Imai
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| |
Collapse
|
39
|
Kizaki K, Ozawa H, Kobayashi T, Matsuoka R, Sakaguchi Y, Fuyuhiro A, Fukuda T, Ishikawa N. Coupling between the photo-excited cyclic π system and the 4f electronic system in a lanthanide single molecule magnet. Chem Commun (Camb) 2017; 53:6168-6171. [PMID: 28534896 DOI: 10.1039/c7cc02960h] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
A new type of electronic interaction which couples two angular momenta, i.e. the angular momentum of a localized 4f system (J) and an orbital angular momentum generated in a cyclic π conjugated system by irradiation with a circularly-polarized light, has been identified in a lanthanide single molecule magnet.
Collapse
Affiliation(s)
- K Kizaki
- Department of Chemistry, Graduate School of Science, Osaka University, Machikaneyamacho, Toyonaka, Osaka 560-0043, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Ozawa H, Matsumoto T, Evyryanti A, Chang J, Harata I, Senda S, Kobayashi T. Stability of human induced pluripotent stem cells cultured in a xeno-free and defined culture medium, Stemfit®. Cytotherapy 2017. [DOI: 10.1016/j.jcyt.2017.02.268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
41
|
Higo S, Iijima N, Ozawa H. Characterisation of Kiss1r (Gpr54)-Expressing Neurones in the Arcuate Nucleus of the Female Rat Hypothalamus. J Neuroendocrinol 2017; 29. [PMID: 27981646 DOI: 10.1111/jne.12452] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/29/2016] [Revised: 11/20/2016] [Accepted: 12/08/2016] [Indexed: 11/30/2022]
Abstract
Kisspeptin is essential in reproduction and acts by stimulating neurones expressing gonadotrophin-releasing hormone (GnRH). Recent studies suggest that kisspeptin has multiple roles in the modulation of neuronal circuits in systems outside the hypothalamic-pituitary-gonadal axis. Our recent research using in situ hybridisation (ISH) clarified the histological distribution of Kiss1r (Gpr54)-expressing neurones in the rat brain that were presumed to be putative targets of kisspeptin. The arcuate nucleus (ARN) of the hypothalamus is one of the brain regions in which Kiss1r expression in non-GnRH neurones is prominent. However, the characteristics of Kiss1r-expressing neurones in the ARN remain unclear. The present study aimed to determine the neurochemical characteristics of Kiss1r-expressing neurones in the ARN using ISH and immunofluorescence. We revealed that the majority (approximately 63%) of Kiss1r-expressing neurones in the ARN were pro-opiomelanocortin (POMC) neurones, which have an anorexic effect in mammals. Additionally, a few Kiss1r-expressing neurones in the dorsal ARN are tuberoinfundibular dopamine (TIDA) neurones, which control milk production by inhibiting prolactin secretion from the anterior pituitary. TIDA neurones showed a relatively weak Kiss1r ISH signal compared to POMC neurones, as well as low co-expression of Kiss1r (approximately 15%). We also examined the expression of Kiss1r in neuropeptide Y and kisspeptin neurones, which are reported to arise from POMC-expressing progenitor cells during development. However, the vast majority of neuropeptide Y and kisspeptin neurones in the ARN did not express Kiss1r. These results suggest that kisspeptin may directly regulate energy homeostasis and milk production by modulating the activity of POMC and TIDA neurones, respectively. Our results provide an insight into the wide variety of roles that kisspeptin plays in homeostatic and neuroendocrine functions.
Collapse
Affiliation(s)
- S Higo
- Department of Anatomy and Neurobiology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
| | - N Iijima
- Department of Anatomy and Neurobiology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
| | - H Ozawa
- Department of Anatomy and Neurobiology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
| |
Collapse
|
42
|
Tomida E, Kato Y, Ozawa H, Hasegawa H, Ishii N, Hashimoto T, Akiyama M. Causative drug detection by drug-induced lymphocyte stimulation test in drug-induced linear IgA bullous dermatosis. Br J Dermatol 2016; 175:1106-1108. [PMID: 26265104 DOI: 10.1111/bjd.14069] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- E Tomida
- Division of Dermatology, Okazaki City Hospital, Okazaki, Japan
| | - Y Kato
- Division of Dermatology, Okazaki City Hospital, Okazaki, Japan
| | - H Ozawa
- Division of Pathology, Okazaki City Hospital, Okazaki, Japan
| | - H Hasegawa
- Division of Surgery, Okazaki City Hospital, Okazaki, Japan
| | - N Ishii
- Department of Dermatology, Kurume University School of Medicine, Kurume, Japan
| | - T Hashimoto
- Kurume University Institute of Cutaneous Cell Biology, Kurume, Japan
| | - M Akiyama
- Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan.
| |
Collapse
|
43
|
Higo S, Honda S, Iijima N, Ozawa H. Mapping of Kisspeptin Receptor mRNA in the Whole Rat Brain and its Co-Localisation with Oxytocin in the Paraventricular Nucleus. J Neuroendocrinol 2016; 28. [PMID: 26709462 DOI: 10.1111/jne.12356] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/29/2015] [Revised: 12/12/2015] [Accepted: 12/21/2015] [Indexed: 11/29/2022]
Abstract
The neuropeptide kisspeptin and its receptor play an essential role in reproduction as a potent modulator of the gonadotrophin-releasing hormone (GnRH) neurone. In addition to its reproductive function, kisspeptin signalling is also involved in extra-hypothalamic-pituitary-gonadal (HPG) axis systems, including oxytocin and arginine vasopressin (AVP) secretion. By contrast to the accumulating information for kisspeptin neurones and kisspeptin fibres, the histological distribution and function of the kisspeptin receptor in the rat brain remain poorly characterised. Using in situ hybridisation combined with immunofluorescence, the present study aimed to determine the whole brain map of Kiss1r mRNA (encoding the kisspeptin receptor), and to examine whether oxytocin or AVP neurones express Kiss1r. Neurones with strong Kiss1r expression were observed in several rostral brain areas, including the olfactory bulb, medial septum, diagonal band of Broca and throughout the preoptic area, with the most concentrated population being around 0.5 mm rostral to the bregma. Co-immunofluorescence staining revealed that, in these rostral brain areas, the vast majority of the Kiss1r-expressing neurones co-expressed GnRH. Moderate levels of Kiss1r mRNA were also noted in the rostral periventricular area, paraventricular nucleus (PVN), and throughout the arcuate nucleus. Relatively weak Kiss1r expression was observed in the supraoptic nucleus and supramammillary nuclei. Moderate to weak expression of Kiss1r was also observed in several regions in the midbrain, including the periaqueductal gray and dorsal raphe nucleus. We also examined whether oxytocin and AVP neurones in the PVN co-express Kiss1r. Immunofluorescence revealed the co-expression of Kiss1r in a subset of the oxytocin neurones but not in the AVP neurones in the PVN. The present study provides a fundamental anatomical basis for further examination of the kisspeptin signalling system in the extra-HPG axis, as well as in reproductive function.
Collapse
Affiliation(s)
- S Higo
- Department of Anatomy and Neurobiology, Graduate School of Medicine, Nippon Medical School, Tokyo, , Japan
| | - S Honda
- Department of Anatomy and Neurobiology, Graduate School of Medicine, Nippon Medical School, Tokyo, , Japan
| | - N Iijima
- Department of Anatomy and Neurobiology, Graduate School of Medicine, Nippon Medical School, Tokyo, , Japan
| | - H Ozawa
- Department of Anatomy and Neurobiology, Graduate School of Medicine, Nippon Medical School, Tokyo, , Japan
| |
Collapse
|
44
|
Imamura M, Nishimikai A, Yanai A, Miyagawa Y, Higuchi T, Ozawa H, Murase K, Takatsuka Y, Miyoshi Y. Abstract P2-08-24: High levels of serum C-terminal crosslinking telopeptide of type 1 collagen at baseline are associated with poor prognosis for breast cancer patients. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-08-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: It has been demonstrated that adjuvant treatment using bisphosphonate may reduce recurrence among breast cancer patients. However, these improved prognoses of patients are reportedly limited to breast cancers of estrogen receptor (ER)-positive and postmenopausal women. Although the mechanisms of the effects of bisphosphonate remain unknown, this finding seems to represent support for the hypothesis that suppression of bone resorption by bisphosphonate results in favorable prognoses at least for patients in this subset. In order to determine the prognostic significance of bone resorption in breast cancer patients, we investigated these markers c-terminal crosslinking telopeptide of type I collagen (1CTP) and N-telopeptide of type I collagen (NTX).
Patients and Methods: 469 breast cancer patients were recruited who were operated on Hyogo College of Medicine and histologically confirmed to have invasive carcinoma. Serum 1CTP and NTX were measured preoperatively with the two-antibody radioimmunoassay and enzyme-linked immunosorbent assay methods, respectively, and blood samples were obtained before treatment from patients who were treated with neoadjuvant chemotherapy or endocrine therapy. The area under receiver operating characteristic curves were applied and optimal cutoff values were set at 3.6ng/ml for 1CTP, and 10.55nmolBCE/L premenopausal and 14.05nmolBCE/L postmenopausal for NTX. The relationships between these bone turnover markers and various clinicopathological characteristics were evaluated with the chi square or Fisher's exact test. The log-rank test was used to compare relapse-free survival (RFS) in Kaplan-Meier plots. Associations of RFS were assessed with a Cox proportional-hazards model based on the results of univariate and multivariate analyses. Differences were considered statistically significant if p<0.05.
Results: There were significantly more 1CTP-high patients among postmenopausal women and RFS of 1CTP-high patients was significantly worse than that of 1CTP-low patients (5-year RFS: 0.65 vs 0.86; p=0.0002). Similarly, NTX-high patients were significantly associated with postmenopausal status, but there was no significant association between NTX-high worse RFS (p=0.0976). Multivariate analysis of tumor size, lymph node metastasis and nuclear grade identified 1CTP (hazard ratio: 2.04, 95% confidence interval: 1.13-3.68; p=0.018) as a significant independent prognostic factor. Subset analyses of 1CTP showed that prognosis was consistently worse recognized for postmenopausal (p=0.0002), but not premenopausal (p=0.37) patients. Furthermore, prognosis for 1CTP-high patients was worse for the estrogen receptor (ER)-positive subset (p=0.0005) but not for the ER-negative subset (p=0.22).
Conclusion and discussion: High levels of serum bone resorption markers at baseline were identified as significant unfavorable prognostic factors for breast cancer patients. The prognostic significance of 1CTP seems to be prominent for postmenopausal patients with ER-positive breast cancers. These findings suggest the use of bone-modifying agents as an adjuvant therapy may be beneficial for breast cancer patients, especially for patients with high serum levels of 1CTP.
Citation Format: Imamura M, Nishimikai A, Yanai A, Miyagawa Y, Higuchi T, Ozawa H, Murase K, Takatsuka Y, Miyoshi Y. High levels of serum C-terminal crosslinking telopeptide of type 1 collagen at baseline are associated with poor prognosis for breast cancer patients. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-08-24.
Collapse
Affiliation(s)
- M Imamura
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - A Nishimikai
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - A Yanai
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Y Miyagawa
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - T Higuchi
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - H Ozawa
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - K Murase
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Y Takatsuka
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Y Miyoshi
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| |
Collapse
|
45
|
Higuchi T, Nishimukai A, Yanai A, Miyagawa Y, Murase K, Imamura M, Ozawa H, Takatsuka Y, Miyoshi Y. Abstract P6-16-01: Differences in patterns of change of bone turnover markers during treatment with bone-modifying agents of breast cancer patients with bone metastases. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-16-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Bone-modifying agents have demonstrated their efficacy for treatment by suppressing osteoclast function. The activity of bone-modifying agents can be monitored by means of bone resorption markers such as c-terminal crosslinking telopeptide of type I collagen (1CTP) and N-telopeptide of type I collagen (NTX) as well as bone forming marker bone-specific alkaline phosphatase (BAP). In contrast to these markers which indirectly indicate bone turnover, tartrate-resistant acid phosphatase-5b (Tracp-5b) has been established as a direct marker showing osteoclast number and activity. The aim of this study was to identify the relative significance of these bone turnover markers as indicators of treatment efficacy induced by bone-modifying agents for breast cancer patients with bone metastases.
Patients and Methods: For this study, 52 breast cancer patients with bone metastases treated with bone-modifying agents were recruited. Zoledronic acid and denosumab were administered as bone-modifying agents to 36 and 22 patients, respectively (for 6 patients, denosumab was used after zoledronic acid). Serum Tracp-5b, 1CTP, NTX and BAP were measured with, respectively, the EIA (enzyme immunoassay), RIA (two-antibody radioimmunoassay), ELISA (enzyme-linked immunosorbent assay) and CLEIA (chemiluminescent enzyme immunoassay) method. Blood samples were obtained pretreatment and 1, 3 and 6 months after treatment. Changes in these bone turnover markers were statistically analyzed with Friedman's test, and correlation between serum markers and clinicopathological factors was calculated with Mann-Whitney's test.
Results: Serum tracp-5b decreased significantly after treatment (p<0.0001). The baseline median value of Tracp-5b (457.5mU/dl, range: 173-1630mU/dl) had been reduced to 137mU/dl (91-795mU/dl) 1 month after treatment, but no further reduction was observed after that. For 13 out of 15 patients to whom Tracp-5b was administered, abnormally high levels (above 420mU/dl) decreased to normal range with one month treatment. Serum NTX was also significantly reduced after treatment (p=0.0007). The median baseline value (16.5nmolBCE/L, 6.1-52.2nmolBCE/L) was diminished after 1 month (to 10.9nmolBCE/L, 7.0-49.5nmolBCE/L), and further reduction of NTX was observed after 3 months (9.55nmolBCE/L, 6.4-56.0nmolBCE/L). Similarly, baseline BAP (15.1μg/L, 6.4-81.3μg/L) decreased significantly (p=0.0032), a reduction which was obtained after 3 months (10.15μg/L, 6.1-51.7μg/L), but not after 1 month (13.0μg/L, 7.7-137.0μg/L). On the other hand, reduction in 1CTP was not significant (p=0.83).
Conclusion and discussion: Although baseline values of the bone turnover markers Tracp-5b, NTX and BAP decreased significantly after treatment with bone-modifying agents, the pattern of reduction for these three markers varied. Tracp-5b appears to reflect efficacy of bone-modifying agents most quickly and sensitively, possibly due to its direct link to the number and activity of osteoclasts. These findings may prove usefulness of Tracp-5b when considering the efficacy of various bone-modifying agents in clinical practice.
Citation Format: Higuchi T, Nishimukai A, Yanai A, Miyagawa Y, Murase K, Imamura M, Ozawa H, Takatsuka Y, Miyoshi Y. Differences in patterns of change of bone turnover markers during treatment with bone-modifying agents of breast cancer patients with bone metastases. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-16-01.
Collapse
Affiliation(s)
- T Higuchi
- Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - A Nishimukai
- Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - A Yanai
- Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Y Miyagawa
- Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - K Murase
- Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - M Imamura
- Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - H Ozawa
- Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Y Takatsuka
- Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Y Miyoshi
- Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| |
Collapse
|
46
|
Ueno H, Kobayashi H, Konishi T, Ishida F, Yamaguchi T, Hinoi T, Kanemitsu Y, Inoue Y, Tomita N, Matsubara N, Komori K, Ozawa H, Nagasaka T, Hasegawa H, Koyama M, Akagi Y, Yatsuoka T, Kumamoto K, Kurachi K, Tanakaya K, Yoshimatsu K, Watanabe T, Sugihara K, Ishida H. Prevalence of laparoscopic surgical treatment and its clinical outcomes in patients with familial adenomatous polyposis in Japan. Int J Clin Oncol 2016; 21:713-722. [PMID: 26820718 DOI: 10.1007/s10147-016-0953-5] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2015] [Accepted: 01/07/2016] [Indexed: 01/01/2023]
Abstract
BACKGROUND Laparoscopic surgery is becoming the preferred technique for most colorectal interventions. This study aimed to clarify the time trend of surgical treatment for familial adenomatous polyposis (FAP) and its relevance to clinical outcomes in Japan over a 13-year period. METHODS This was a multicenter retrospective cohort study comprising 23 specialist institutions for colorectal disease and a cohort of 282 FAP patients who underwent total colectomy or proctocolectomy during 2000-2012. Patient clinical backgrounds and surgical outcomes were compared between the first and second halves of the study period. RESULTS The proportion of surgical types adopted over the entire study period was 46, 21, 30, and 3 % for ileoanal anastomosis (IAA), ileoanal canal anastomosis, ileorectal anastomosis, and permanent ileostomy, respectively. FAP patients undergoing laparoscopic surgery have increased since 2008 and reached 74 % in the past 3 years. In particular, the number of patients undergoing laparoscopic proctocolectomy with IAA increased approximately four-fold from the first to the second half of the study period. A laparoscopic approach was increasingly used in patients with coexisting colorectal malignancies. Despite this trend, surgical results of the laparoscopic approach between the two study periods showed similar morbidity, pouch operation and stoma closure completion rates. No postoperative mortality was observed in this series, and laparoscopic surgery was comparable to open surgery in terms of stoma closure rate, incidence of intra-abdominal/abdominal desmoid tumors, and postoperative survival rate in both study periods. CONCLUSION Laparoscopic approach is increasingly being adopted for prophylactic FAP surgery in Japan and may provide clinically acceptable practical outcomes.
Collapse
Affiliation(s)
- Hideki Ueno
- Department of Surgery, National Defense Medical College, Tokorozawa, Saitama, 359-8513, Japan.
| | - Hirotoshi Kobayashi
- Center for Minimally Invasive Surgery, Tokyo Medical and Dental University, Tokyo, Japan
| | - Tsuyoshi Konishi
- Gastroenterological Center, Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
| | - Fumio Ishida
- Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan
| | - Tatsuro Yamaguchi
- Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
| | - Takao Hinoi
- Department of Gastroenterological and Transplant Surgery, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Yukihide Kanemitsu
- Division of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan
| | - Yasuhiro Inoue
- Department of Gastrointestinal and Pediatric Surgery, Mie University Graduate School of Medicine, Tsu, Japan
| | - Naohiro Tomita
- Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan
| | | | - Koji Komori
- Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Heita Ozawa
- Department of Surgery, Tochigi Cancer Center, Utsunomiya, Japan
| | - Takeshi Nagasaka
- Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | | | - Motoi Koyama
- Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
| | - Yoshito Akagi
- Department of Surgery, Kurume University School of Medicine, Kurume, Japan
| | - Toshimasa Yatsuoka
- Department of Gastroenterological Surgery, Saitama Cancer Center, Saitama, Japan
| | - Kensuke Kumamoto
- Department of Organ Regulatory Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan
| | - Kiyotaka Kurachi
- Department of Surgery 2, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Kohji Tanakaya
- Department of Surgery, Iwakuni Clinical Center, Iwakuni, Japan
| | - Kazuhiko Yoshimatsu
- Department of Surgery, Tokyo Women's Medical University Medical Center East, Tokyo, Japan
| | - Toshiaki Watanabe
- Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | | | - Hideyuki Ishida
- Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan
| |
Collapse
|
47
|
Kanno H, Ozawa H, Koizumi Y, Morozumi N, Aizawa T, Itoi E. Increased Facet Fluid Predicts Dynamic Changes in the Dural Sac Size on Axial-Loaded MRI in Patients with Lumbar Spinal Canal Stenosis. AJNR Am J Neuroradiol 2015; 37:730-5. [PMID: 26564439 DOI: 10.3174/ajnr.a4582] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Accepted: 08/18/2015] [Indexed: 01/17/2023]
Abstract
BACKGROUND AND PURPOSE Axial-loaded MR imaging, which simulates the spinal canal in a standing position, demonstrates reductions of the dural sac cross-sectional area in patients with lumbar spinal canal stenosis. However, there has been no useful conventional MR imaging finding for predicting a reduction in the dural sac cross-sectional area on axial-loaded MR imaging. Previous studies have shown that increased facet fluid is associated with the spinal instability detected during positional changes. The purpose of this study was to analyze the correlations between facet fluid and dynamic changes in the dural sac cross-sectional area on axial-loaded MR imaging. MATERIALS AND METHODS In 93 patients with lumbar spinal canal stenosis, the dural sac cross-sectional area was measured by using axial images of conventional and axial-loaded MR imaging. Changes in the dural sac cross-sectional area induced by axial loading were calculated. The correlation between the facet fluid width measured on conventional MR imaging and the change in dural sac cross-sectional area was analyzed. The change in the dural sac cross-sectional area was compared between the intervertebral levels with and without the facet fluid width that was over the cutoff value determined in this study. RESULTS The dural sac cross-sectional area was significantly smaller on axial-loaded MR imaging than on conventional MR imaging. The facet fluid width significantly correlated with the change in the dural sac cross-sectional area (r = 0.73, P < .001). The change in the dural sac cross-sectional area at the intervertebral level with the facet fluid width over the cutoff value was significantly greater than that at the other level. CONCLUSIONS The increased facet fluid on conventional MR imaging is highly predictive of the dynamic reduction of dural sac cross-sectional area detected on axial-loaded MR imaging in the clinical assessment of lumbar spinal canal stenosis.
Collapse
Affiliation(s)
- H Kanno
- From the Department of Orthopedic Surgery (H.K., H.O., T.A., E.I.), Tohoku University School of Medicine, Sendai, Japan
| | - H Ozawa
- From the Department of Orthopedic Surgery (H.K., H.O., T.A., E.I.), Tohoku University School of Medicine, Sendai, Japan
| | - Y Koizumi
- Department of Orthopedic Surgery (Y.K., N.M.), Sendai Nishitaga National Hospital, Sendai, Japan
| | - N Morozumi
- Department of Orthopedic Surgery (Y.K., N.M.), Sendai Nishitaga National Hospital, Sendai, Japan
| | - T Aizawa
- From the Department of Orthopedic Surgery (H.K., H.O., T.A., E.I.), Tohoku University School of Medicine, Sendai, Japan
| | - E Itoi
- From the Department of Orthopedic Surgery (H.K., H.O., T.A., E.I.), Tohoku University School of Medicine, Sendai, Japan
| |
Collapse
|
48
|
Ito S, Nemoto T, Tsujino N, Ohmuro N, Matsumoto K, Matsuoka H, Tanaka K, Nishiyama S, Suzuki M, Kinoshita H, Ozawa H, Fujita H, Shimodera S, Kishimoto T, Matsumoto K, Hasegawa T, Mizuno M. Differential impacts of duration of untreated psychosis (DUP) on cognitive function in first-episode schizophrenia according to mode of onset. Eur Psychiatry 2015; 30:995-1001. [DOI: 10.1016/j.eurpsy.2015.08.004] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/22/2015] [Revised: 08/17/2015] [Accepted: 08/18/2015] [Indexed: 01/10/2023] Open
Abstract
AbstractBackgroundThe mode of onset and the course of schizophrenia illness exhibit substantial individual variations. Previous studies have pointed out that the mode of onset affects the duration of untreated psychosis (DUP) and clinical outcomes, such as cognitive and social functioning. This study attempted to clarify the association between the DUP and clinical features, taking the different modes of onset into consideration, in a prospective longitudinal study examining patients with first-episode schizophrenia.MethodsThis study was conducted in six areas of Japan. Patients with first-episode schizophrenia were followed for over 18 months. Cognitive function, psychopathology, and social functioning were assessed at baseline and at 6, 12, and 18-month follow-up points.ResultsWe identified 168 patients and sufficient information was available to determine the DUP and the mode of onset for 156 patients (92.9%): 79 had an acute onset, and 77 had an insidious onset. The DUP was significantly associated with quality of life (QOL), social functioning, and cognitive function at most of the follow-up points in the insidious-onset group. The DUP and negative symptoms at baseline were significant predictors of cognitive function at the 18-month follow-up in the insidious-onset group.ConclusionsThe present results further support the hypothesis that the DUP affects QOL, social functioning, and cognitive function over the course of illness, especially in patients with an insidious onset. Effective strategies for detecting and caring for individuals with insidious onset early during the course of schizophrenia will be essential for achieving a full patient recovery.
Collapse
|
49
|
Kimura H, Takahashi K, Futami K, Ikeuchi H, Tatsumi K, Watanabe K, Maeda K, Watadani Y, Nezu R, Kameyama H, Nakao S, Kurachi K, Hotokezaka M, Otsuka K, Watanabe T, Ozawa H. Has widespread use of biologic and immunosuppressant therapy for ulcerative colitis affected surgical trends? Results of a questionnaire survey of surgical institutions in Japan. Surg Today 2015; 46:930-8. [PMID: 26467558 DOI: 10.1007/s00595-015-1259-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2015] [Accepted: 09/17/2015] [Indexed: 12/20/2022]
Abstract
PURPOSE The aim of the study is to assess the relationship between the introduction of biologic and immunosuppressant therapy and the number of patients undergoing surgery for ulcerative colitis (UC). METHODS A questionnaire survey about patients undergoing surgery for UC was sent to 26 teaching hospitals throughout Japan. The questionnaire period spanned from 2008 to 2013, to account for the introduction of tacrolimus (2009) and infliximab (2010). RESULTS The total number of patients who underwent surgery was 297, 291, 273, 255, 300, and 305 in 2008, 2009, 2010, 2011 2012, and 2013, respectively. The emergency surgery rate remained stable at 32-34 % each year. The proportion of patients who underwent surgery for cancer increased from 13.8 % in 2008 to 20 % in 2013. In 2013, 41, 38, and 6 % of patients who underwent surgery had received treatment with a biologic, tacrolimus, and cyclosporine, respectively. No institution reported an increase in postoperative complications among patients treated with immunosuppressive drugs. CONCLUSIONS The number of patients undergoing surgery decreased temporarily soon after infliximab and tacrolimus first became widely available, but subsequently increased again. The emergency surgery rate remained unchanged throughout the study period. These data show that immunosuppressive drugs have had little effect on the risk of postoperative complications.
Collapse
Affiliation(s)
- Hideaki Kimura
- Inflammatory Bowel Disease Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Kanagawa, Japan.
| | - Kenichi Takahashi
- Department of Colorectal Surgery, Tohoku Rosai Hospital, Sendai, Miyagi, Japan
| | - Kitaro Futami
- Department of Surgery, Fukuoka University Chikushi Hospital, Chikushino, Fukuoka, Japan
| | - Hiroki Ikeuchi
- Inflammatory Bowel Disease Center, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Kenji Tatsumi
- Inflammatory Bowel Disease Center, Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan
| | - Kazuhiro Watanabe
- Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - Kiyoshi Maeda
- Department of Surgical Oncology, Osaka City University School of Medicine, Osaka, Japan
| | - Yusuke Watadani
- Department of Surgery, Hiroshima University, Hiroshima, Japan
| | - Riichiro Nezu
- Department of Surgery, Nishinomiya Municipal Central Hospital, Nishinomiya, Hyogo, Japan
| | - Hitoshi Kameyama
- Division of Digestive and General Surgery, Niigata University, Niigata, Japan
| | - Sayumi Nakao
- Second Department of Surgery, Tokyo Women's Medical University, Tokyo, Japan
| | - Kiyotaka Kurachi
- Second Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | | | - Koki Otsuka
- Department of Surgery, Iwate Medical University School of Medicine, Morioka, Iwate, Japan
| | - Toshiaki Watanabe
- Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan
| | - Heita Ozawa
- Division of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan
| |
Collapse
|
50
|
Kotake K, Kobayashi H, Asano M, Ozawa H, Sugihara K. Influence of extent of lymph node dissection on survival for patients with pT2 colon cancer. Int J Colorectal Dis 2015; 30:813-20. [PMID: 25808013 DOI: 10.1007/s00384-015-2194-x] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/11/2015] [Indexed: 02/04/2023]
Abstract
PURPOSE The optimal extent of lymph node dissection for early-stage colon cancer (CC) remains undefined. This study assessed the influence of the extent of lymph node dissection on overall survival (OS) in patients with pT2 CC. METHODS We retrospectively examined data from the multi-institutional registry system of the Japanese Society for Cancer of the Colon and Rectum and used a propensity score matching method to balance potential confounders of lymph node dissection. We extracted 463 matched pairs from 1433 patients who underwent major resections for pT2 CC between 1995 and 2004. RESULTS Lymph node metastasis was found in 301 (21.0%) of 1433 patients with pT2 CC. In this cohort, significant independent risk factors for lymph node metastasis were lymphatic invasion and venous invasion. Patients who underwent D3 or D2 lymph node dissection did not significantly differ in OS, either among the propensity score-matched cohort (estimated hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.536-1.346, P = 0.484) or in the cohort as a whole (HR 0.720, 95% CI 0.492-1.052, P = 0.089). CONCLUSIONS For patients with pT2 CC, D3 lymph node dissection did not add to OS. D2 lymph node dissection may be adequate for pT2 CC.
Collapse
Affiliation(s)
- Kenjiro Kotake
- Department of Colorectal Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan,
| | | | | | | | | |
Collapse
|